

<b>7.01.05 Cochlear Implant</b>	
<b>Original Policy Date:</b> March 5, 1986	<b>Effective Date:</b> April 1, 2024
<b>Section:</b> 7.0 Surgery	<b>Page:</b> Page 1 of 35

**Policy Statement**

- I. Bilateral or unilateral cochlear implantation of a U.S. Food and Drug Administration (FDA)-approved cochlear implant may be considered **medically necessary** in individuals who meet **all** of the following criteria:
  - A. Individual’s age is 9 months and older
  - B. Individual has bilateral severe-to-profound pre- or post-lingual (sensorineural) hearing loss, defined as a hearing threshold pure-tone average of 70 dB hearing loss or greater at 500, 1000, and 2000 Hz
  - C. Individual has shown limited or no benefit from hearing aids
  
- II. Cochlear implantation as a treatment for individuals with unilateral hearing loss with or without tinnitus is considered **investigational**.
  
- III. The following are considered **investigational**:
  - A. Upgrades of an existing, functioning external system to achieve aesthetic improvement, such as smaller profile components or a switch from a body-worn, external sound processor to a behind-the-ear model
  - B. Replacement of internal and/or external components solely for the purpose of upgrading to a system with advanced technology or to a next-generation device
  
- IV. Replacement of internal and/or external components may be considered **medically necessary** only in a small subset of members who have inadequate response to existing component(s) to the point of interfering with the individual’s activities of daily living, or the component(s) is/are no longer functional and cannot be repaired. Copies of original medical records must be submitted either hard copy or electronically to support medical necessity.
  
- V. Cochlear implantation with a hybrid cochlear implant/hearing aid device that includes the hearing aid integrated into the external sound processor of the cochlear implant (e.g., the Nucleus® Hybrid™ L24 Cochlear Implant System) may be considered **medically necessary** for individuals ages 18 years and older who meet **all** of the following criteria:
  - A. Bilateral severe-to-profound high-frequency sensorineural hearing loss with residual low-frequency hearing sensitivity
  - B. Receive limited benefit from appropriately fit bilateral hearing aids
  - C. Have **all** of the following hearing thresholds:
    - 1. Low-frequency hearing thresholds no poorer than 60 dB hearing level up to and including 500 Hz (averaged over 125, 250, and 500 Hz) in the ear selected for implantation
    - 2. Severe-to-profound mid- to high-frequency hearing loss (threshold average of 2000, 3000, and 4000 Hz greater than or equal to 75 dB hearing level) in the ear to be implanted
    - 3. Moderately severe to profound mid- to high-frequency hearing loss (threshold average of 2000, 3000, and 4000 Hz greater than or equal to 60 dB hearing level) in the contralateral ear
    - 4. Aided consonant-nucleus-consonant word recognition score from 10% to 60% in the ear to be implanted in the preoperative aided condition and in the contralateral ear will be equal to or better than that of the ear to be implanted but not more than 80% correct

An independent member of the Blue Shield Association

**NOTE:** Refer to [Appendix A](#) to see the policy statement changes (if any) from the previous version.

## Policy Guidelines

Bilateral cochlear implantation should be considered only when it has been determined that the alternative of unilateral cochlear implantation plus hearing aid in the contralateral ear will not result in a binaural benefit (i.e., in those individuals with hearing loss of a magnitude where a hearing aid will not produce the required amplification).

In certain situations, implantation may be considered before 12 months of age. One scenario is after meningitis when cochlear ossification may preclude implantation. Another is in cases with a strong family history, because establishing a precise diagnosis is less uncertain.

Hearing loss is rated based on the threshold of hearing. Severe hearing loss is defined as a bilateral hearing threshold of 70 to 90 dB, and profound hearing loss is defined as a bilateral hearing threshold of 90 dB and above.

In adults, limited benefit from hearing aids is defined as scores of 50% correct or less in the ear to be implanted on tape-recorded sets of open-set sentence recognition. In children, limited benefit is defined as failure to develop basic auditory skills, and in older children, 30% or less correct on open-set tests.

A post cochlear implant rehabilitation program is necessary to achieve benefit from the cochlear implant. The rehabilitation program consists of 6 to 10 sessions that last approximately 2.5 hours each. The rehabilitation program includes development of skills in understanding running speech, recognition of consonants and vowels, and tests of speech perception ability.

Contraindications to cochlear implantation may include deafness due to lesions of the eighth cranial (acoustic) nerve, central auditory pathway, or brainstem; active or chronic infections of the external or middle ear; and mastoid cavity or tympanic membrane perforation. Cochlear ossification may prevent electrode insertion, and the absence of cochlear development as demonstrated on computed tomography scans remains an absolute contraindication.

## Description

A cochlear implant is a device for treatment of severe-to-profound hearing loss in individuals who only receive limited benefit from amplification with hearing aids. A cochlear implant provides direct electrical stimulation to the auditory nerve, bypassing the usual transducer cells that are absent or nonfunctional in deaf cochlea.

## Related Policies

- Auditory Brainstem Implant
- Implantable Bone-Conduction and Bone-Anchored Hearing Aids
- Semi-Implantable and Fully Implantable Middle Ear Hearing Aids
- Treatment of Tinnitus

## Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract

language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

**Regulatory Status**

Several cochlear implants are commercially available in the United States and are manufactured by Cochlear Americas, Advanced Bionics, and the MED-EL Corp. Over time, subsequent generations of the various components of the devices have been approved by the U.S. Food and Drug Administration (FDA), focusing on improved electrode design and speech-processing capabilities. Furthermore, smaller devices and the accumulating experience in children have resulted in broadening of the selection criteria to include children as young as 12 months. The labeled indications from the FDA for currently marketed implant devices are summarized in Table 1. FDA product code: MCM.

**Table 1. Cochlear Implant Systems Approved by the U.S. Food and Drug Administration**

Variables Manufacturer and Currently Marketed Cochlear Implants				
Device	Advanced Bionics® HiResolution® Bionic Ear System (HiRes 90K)	Cochlear® Nucleus 22 and 24	Med El® Maestro Combi 40+	Neuro Cochlear Implant System (Oticon Medical)
PMA	P960058	P840024, P970051	P000025	P200021
Indications				
Adults ≥18 y	<ul style="list-style-type: none"> <li>• Postlingual onset of severe-to-profound bilateral SNHL (≥70 dB)</li> <li>• Limited benefit from appropriately fitted hearing aids, defined as scoring ≤50% on a test of open-set HINT sentence recognition</li> </ul>	<ul style="list-style-type: none"> <li>• Pre-, peri-, or postlingual onset of bilateral SNHL, usually characterized by:                             <ul style="list-style-type: none"> <li>○ Moderate-to-profound HL in low frequencies; and</li> <li>○ Profound (≥90 dB) HL in mid-to-high speech frequencies</li> </ul> </li> <li>• Severe to profound unilateral SNHL (SSD or AHL)                             <ul style="list-style-type: none"> <li>○ PTA at 500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Severe-to-profound bilateral SNHL (≥70 dB)</li> <li>• ≤40% correct HINT sentences with best-sided listening condition</li> <li>• SSD (≥90 dB) or AHL (Δ15 dB PTA)</li> <li>• Limited benefit from unilateral amplification, defined by test scores of 5% or less on monosyllabic CNC words in quiet when tested in the ear to be</li> </ul>	<ul style="list-style-type: none"> <li>• Severe-to-profound bilateral SNHL (≥70 dB at 500, 1000, and 2000 Hz)</li> <li>• Limited benefit from appropriately fit hearing aids, defined as scoring ≤50% correct HINT sentences in quiet or noise with best-sided listening condition</li> </ul>

**Variables Manufacturer and Currently Marketed Cochlear Implants**

			<ul style="list-style-type: none"> <li>○ of &gt; 80 dB HL</li> <li>○ Normal or near normal hearing in the contralateral ear defined as PTA at 500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz of <math>\leq 30</math> dB HL</li> <li>○ Limited benefit from an appropriately fitted unilateral hearing device</li> </ul>	<ul style="list-style-type: none"> <li>○ implanted alone</li> <li>○ Patients must have at least 1 month experience wearing a CROS hearing aid or other relevant device and not show any subjective benefit</li> </ul>
<b>Children</b>	12 mo to 17 y of age	25 mo to 17 y, 11 mo of age	12 mo to 18 y of age	Not applicable
	<ul style="list-style-type: none"> <li>● Profound bilateral SNHL (&gt;90 dB) Use of appropriately fitted hearing aids for at least 6 mo in children 2 to 17 y or at least 3 mo in children 12 to 23 mo</li> <li>● Lack of benefit in children &lt;4 y defined as a failure to reach developmentally appropriate auditory milestones (e.g., spontaneous response to name in</li> </ul>	<ul style="list-style-type: none"> <li>● Severe-to-profound bilateral SNHL</li> <li>● MLNT scores <math>\leq 30\%</math> in best-aided condition in children</li> <li>● LNT scores <math>\leq 30\%</math> in best-aided condition in children</li> </ul> <p>9 to 24 mo of age</p> <ul style="list-style-type: none"> <li>● Profound SNHL bilaterally</li> <li>● Limited benefit from appropriate binaural hearing aids</li> </ul> <p>5 y to 18 y of age</p> <ul style="list-style-type: none"> <li>● Severe to profound unilateral SNHL (SSD or AHL)                             <ul style="list-style-type: none"> <li>○ PTA at 500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>● Profound sensorineural HL (<math>\geq 90</math> dB)</li> <li>○ In younger children, little or no benefit is defined by lack of progress in the development of simple auditory skills with hearing aids over 3 to 6 mo</li> <li>○ In older children, lack of aided benefit is defined as &lt;20% correct on the MLNT or LNT, depending</li> </ul>	

**Variables Manufacturer and Currently Marketed Cochlear Implants**

<p>quiet or to environment al sounds) measured using IT-MAIS or MAIS or &lt;20% correct on a simple open-set word recognition test (MLNT) administered using monitored live voice (70 dB SPL)</p>	<ul style="list-style-type: none"> <li>○ Normal or near normal hearing in the contralateral ear defined as PTA at 500 Hz, 1000 Hz, 2000 Hz, and 4000 Hz of <math>\leq 30</math> dB HL</li> </ul>	<p>of &gt; 80 dB HL</p>	<p>on child’s cognitive ability and linguistic skills</p> <ul style="list-style-type: none"> <li>○ A 3- to 6- mo trial with hearing aids is required if not previously experienced</li> </ul> <p>5 y to 18 y of age</p> <ul style="list-style-type: none"> <li>• SSD (<math>\geq 90</math> dB) or AHL (<math>\Delta 15</math> dB PTA)</li> <li>•</li> </ul>
<ul style="list-style-type: none"> <li>• Lack of hearing aid benefit in children &gt;4 y defined as scoring &lt;12% on a difficult open-set word recognition test (PBK test) or &lt;30% on an open-set sentence test (HINT for Children) administered using recorded materials in the sound field (70 dB SPL)</li> </ul>	<ul style="list-style-type: none"> <li>• Limited benefit from an appropriately fitted unilateral hearing device</li> </ul>		<ul style="list-style-type: none"> <li>○ Insufficient functional access to sound in the ear to be implanted must be determined by aided speech perception test scores of 5% or less on developmentally appropriate monosyllabic word lists when tested in the ear to be implanted</li> <li>○ Patients must have at least 1 month experience wearing a CROS hearing aid or other relevant device and not show any subjective benefit</li> </ul>

AHL: asymmetric hearing loss; CNC: consonant-nucleus-consonant; CROS: contralateral routing of signal; HINT: Hearing in Noise Test; HL: hearing loss; IT-MAIS: Infant-Toddler Meaningful Auditory Integration Scale; LNT:

Lexical Neighborhood Test; MAIS: Meaningful Auditory Integration Scale; MLNT: Multisyllabic Lexical Neighborhood Test; PBK: Phonetically Balanced-Kindergarten; PMA: premarket approval; PTA: pure tone average; SNHL: sensorineural hearing loss; SPL: sound pressure level; SSD: single-sided deafness.

In 2014, the Nucleus<sup>®</sup> Hybrid™ L24 Cochlear Implant System (Cochlear Americas) was approved by the FDA through the premarket approval (PMA) process. This system is a hybrid cochlear implant and hearing aid, with the hearing aid integrated into the external sound processor of the cochlear implant. It is indicated for unilateral use in patients aged 18 years and older who have residual low-frequency hearing sensitivity and severe-to-profound high-frequency sensorineural hearing loss, and who obtain limited benefit from an appropriately fit bilateral hearing aid. The electrode array inserted into the cochlea is shorter than conventional cochlear implants. According to the FDA's PMA notification, labeled indications for the device include:

- Preoperative hearing in the range from "normal to moderate hearing loss [HL] in the low frequencies (thresholds no poorer than 60 dB HL up to and including 500 Hz)"
- Preoperative hearing with "severe to profound mid to high frequency hearing loss (threshold average of 2000, 3000, and 4000 Hz  $\geq$ 75 dB HL) in the ear to be implanted"
- Preoperative hearing with "moderately severe to profound mid to high frequency hearing loss (threshold average of 2000, 3000, and 4000 Hz  $\geq$ 60 dB HL) in the contralateral ear"
- "The CNC [Consonant-Nucleus-Consonant] word recognition score will be between 10% and 60%, inclusively, in the ear to be implanted in the preoperative aided condition and in the contralateral ear equal to or better than that of the ear to be implanted but not more than 80% correct."

In 2022, the Nucleus<sup>®</sup> Hybrid™ L24 Cochlear Implant System received expanded approval for single-sided deafness or unilateral hearing loss in adults and children age 5 or older (P970051/S205). Other hybrid hearing devices have been developed. The Med-El EAS System received expanded PMA by the FDA in 2016 (PMA P000025/S084). FDA product code: PGQ.

Although cochlear implants have typically been used unilaterally, interest in bilateral cochlear implantation has arisen in recent years. The proposed benefits of bilateral cochlear implants are to improve understanding of speech occurring in noisy environments and localization of sounds. Improvements in speech intelligibility with bilateral cochlear implants may occur through binaural summation (i.e., signal processing of sound input from 2 sides may provide a better representation of sound and allow the individual to separate noise from speech). Speech intelligibility and localization of sound or spatial hearing may also be improved with head shadow and squelch effects (i.e., the ear that is closest to the noise will receive it at a different frequency and with different intensity, allowing the individual to sort out the noise and identify the direction of sound). Bilateral cochlear implantation may be performed independently with separate implants and speech processors in each ear, or a single processor may be used. However, no single processor for bilateral cochlear implantation has been approved by the FDA for use in the United States. Also, single processors do not provide binaural benefit and may impair sound localization and increase the signal-to-noise ratio received by the cochlear implant.

## Rationale

### Background

The basic structure of a cochlear implant includes both external and internal components. The external components include a microphone, an external sound processor, and an external transmitter. The internal components are implanted surgically and include an internal receiver implanted within the temporal bone and an electrode array that extends from the receiver into the cochlea through a surgically created opening in the round window of the middle ear.

Sounds picked up by the microphone are carried to the external sound processor, which transforms sound into coded signals that are then transmitted transcutaneously to the implanted internal

receiver. The receiver converts the incoming signals into electrical impulses that are then conveyed to the electrode array, ultimately resulting in stimulation of the auditory nerve.

### **Literature Review**

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function<sup>3/4</sup>including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Promotion of greater diversity and inclusion in clinical research of historically marginalized groups (e.g., People of Color [African-American, Asian, Black, Latino and Native American]; LGBTQIA (Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual); Women; and People with Disabilities [Physical and Invisible]) allows policy populations to be more reflective of and findings more applicable to our diverse members. While we also strive to use inclusive language related to these groups in our policies, use of gender-specific nouns (e.g., women, men, sisters, etc.) will continue when reflective of language used in publications describing study populations.

### **Cochlear Implantation for Bilateral Sensorineural Hearing Loss**

#### **Clinical Context and Therapy Purpose**

The purpose of cochlear implants is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as best-aided hearing, in individuals with bilateral sensorineural hearing loss.

Contraindications to cochlear implantation may include deafness due to lesions of the eighth cranial (acoustic) nerve, central auditory pathway, or brainstem; active or chronic infections of the external or middle ear; and mastoid cavity or tympanic membrane perforation. Cochlear ossification may prevent electrode insertion, and the absence of cochlear development as demonstrated on computed tomography scans remains an absolute contraindication.

The following PICO was used to select literature to inform this review.

#### ***Populations***

The relevant population of interest are individuals with bilateral sensorineural hearing loss.

#### ***Interventions***

The therapy being considered is the cochlear implant, which has both external and internal components. The external components include a microphone, an external sound processor, and an external transmitter. The internal components are implanted surgically and include an internal receiver implanted within the temporal bone and an electrode array that extends from the receiver into the cochlea through a surgically created opening in the round window of the middle ear.

### ***Comparators***

Comparators of interest include best-aided hearing.

### ***Outcomes***

The general outcomes of interest are symptoms, functional outcomes, treatment-related mortality, and treatment-related morbidity.

The existing literature evaluating cochlear implant(s) as a treatment for bilateral sensorineural hearing loss has varying lengths of follow-up, ranging from 6 months. While studies described below all reported at least one outcome of interest, longer follow-up was necessary to fully observe outcomes. Therefore, 1-year of follow-up is considered necessary to demonstrate efficacy.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess longer-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

### **Review of Evidence**

#### **Cochlear Implantation: Unilateral Stimulation**

Cochlear implants are recognized as an effective treatment of sensorineural deafness, as noted in a 1995 National Institutes of Health Consensus Development Conference, which offered the following conclusions<sup>1</sup>:

"Cochlear implantation improves communication ability in most adults with severe to profound deafness and frequently leads to positive psychological and social benefits as well."

"Prelingually deafened adults may also be suitable for implantation, although these candidates must be counseled regarding realistic expectations. Existing data indicate that these individuals achieve minimal improvement in speech recognition skills.

However, other basic benefits, such as improved sound awareness, may provide psychological satisfaction meet safety needs."

"...training and educational intervention are fundamental for optimal postimplant benefit."

The effectiveness of cochlear implants has been evaluated in several systematic reviews and technology assessments, both from the United States and abroad. Bond et al (2009) authored a technology assessment to investigate the clinical and cost-effectiveness of unilateral cochlear implants (using or not using hearing aids) and bilateral cochlear implants compared with a single cochlear implant (unilateral or unilateral plus hearing aids) for severely to profoundly deaf children and adults.<sup>2</sup> The clinical effectiveness review included 33 articles (1513 deaf children; 1379 adults), 2 of which were RCTs. They defined 62 different outcome measures, and overall evidence was of moderate-to-poor quality. Reviewers concluded: "Unilateral cochlear implantation is safe and effective for adults and children and likely to be cost-effective in profoundly deaf adults and profoundly and prelingually deaf children."

Gaylor et al (2013) published an updated technology assessment for the Agency for Healthcare Research and Quality.<sup>3</sup> Sixteen (of 42) studies published through May 2012 evaluated unilateral cochlear implants. Most unilateral implant studies showed statistically significant improvement in mean speech scores, as measured by open-set sentence or multisyllable word tests; meta-analysis of 4 studies revealed significant improvements in cochlear implant relevant quality of life after unilateral implantation (standard mean difference [SMD], 1.71; 95% confidence interval [CI], 1.15 to



2.27). However, these studies varied in design, and considerable heterogeneity was observed across studies.

### **Cochlear Implantation: Bilateral Stimulation**

While the use of unilateral cochlear implants in patients with severe-to-profound hearing loss has become a well-established intervention, bilateral cochlear implantation is becoming more common. Many publications have reported slight-to-modest improvements in sound localization and speech intelligibility with bilateral cochlear implants, especially with noisy backgrounds but not necessarily in quiet environments. When reported, the combined use of binaural stimulation improved hearing by a few decibels or percentage points.

In a meta-analysis, McRackan et al (2018) determined the impact of cochlear implantation on quality of life and determined the correlation. From 14 articles with 679 cochlear implant patients who met the inclusion criteria, pooled analyses of all hearing-specific quality of life measures revealed a very strong improvement in quality of life after cochlear implantation (SMD, 51.77).<sup>4</sup> Subset analysis of cochlear implant-specific quality of life measures also showed very strong improvement (SMD, 51.69). Thirteen articles with 715 patients met the criteria to evaluate associations between quality of life and speech recognition. Pooled analyses showed a low positive correlation between hearing-specific quality of life and word recognition in quiet ( $r=50.213$ ), sentence recognition in quiet ( $r=50.241$ ), and sentence recognition in noise ( $r=50.238$ ). Subset analysis of cochlear implant-specific quality of life showed similarly low positive correlations with word recognition in quiet ( $r=50.213$ ), word recognition in noise ( $r=50.241$ ), and sentence recognition in noise ( $r=50.255$ ) between quality of life and speech recognition ability. Using hearing-specific and cochlear implant-specific measures of quality of life, patients report significantly improved quality of life after cochlear implantation. This study is limited in that widely used clinical measures of speech recognition are poor predictors of patient-reported quality of life with cochlear implants.

In another meta-analysis, McRackan et al (2018) aimed to determine the change in general health-related quality of life (HRQOL) after cochlear implantation and association with speech recognition.<sup>5</sup> Twenty-two articles met criteria for meta-analysis of HRQOL improvement, but 15 (65%) were excluded due to incomplete statistical reporting. From the 7 articles with 274 cochlear implant patients that met inclusion criteria, pooled analyses showed a medium positive effect of cochlear implantation on HRQOL (SMD, 0.79). Subset analysis of the Health Utilities Index 3 measure showed a large effect (SMD, 0.84). Nine articles with 550 cochlear implant patients met inclusion criteria for meta-analysis of correlations between non-disease specific patient-reported outcome measures and speech recognition after cochlear implantation (word recognition in quiet [ $r=0.35$ ], sentence recognition in quiet [ $r=0.40$ ], and sentence recognition in noise [ $r=0.32$ ]). Some limitations are, though regularly used, HRQOL measures are not intended to measure nor do they accurately reflect the complex difficulties facing cochlear implant patients. Only a medium positive effect of cochlear implantation on HRQOL was observed along with a low correlation between non-disease specific patient-reported outcome measures and speech recognition. The use of such instruments in this population may underestimate the benefit of cochlear implantation.

Crathorne et al (2012) published a systematic review.<sup>6</sup> The objective was to evaluate the clinical and cost-effectiveness of bilateral multichannel cochlear implants compared with unilateral cochlear implantation alone or in conjunction with an acoustic hearing aid in adults with severe-to-profound hearing loss. A literature search was updated through January 2012. Nineteen studies conducted in the United States and Europe were included. The review included 2 RCTs with waiting-list controls, 10 studies with prospective pre/post repeated-measure or cohort designs, 6 cross-sectional studies, and an economic evaluation. All studies compared bilateral with unilateral implantation, and 2 compared bilateral implants with a unilateral implant plus acoustic hearing aid. The studies selected were of moderate-to-poor quality, including both RCTs. Meta-analyses could not be performed due to heterogeneity among studies in outcome measures and study designs. However, all studies reported that bilateral cochlear implants improved hearing and speech perception. One RCT found a

significant binaural benefit over the first ear alone for speech and noise from the front (12.6%;  $p < .001$ ) and when noise was ipsilateral to the first ear (21%;  $p < .001$ ); another RCT found a significant benefit for spatial hearing at 3 months postimplantation compared with preimplantation (mean difference [MD], 1.46;  $p < .01$ ). Quality of life results varied, showing bilateral implantation might improve quality of life in the absence of worsening tinnitus.

The Gaylor Agency for Healthcare Research and Quality assessment (previously reported) showed improvement across 13 studies in communication-related outcomes with bilateral implantation compared with unilateral implantation and additional improvements in sound localization compared with unilateral device use or implantation only.<sup>3</sup> The risk of bias varied from medium to high across studies. Based on results from at least 2 studies, quality of life outcomes varied across tests after bilateral implantation; meta-analysis was not performed because of heterogeneity in designs across studies.

Since the publication of the systematic reviews described above, additional comparative studies and case series have reported on outcomes after bilateral cochlear implantation. For example, in a 2016 prospective observational study including 113 patients with postlingual hearing loss, of whom 50 were treated with cochlear implants and 63 with hearing aids, cochlear implant recipients' depression scores improved from preimplantation to 12 months posttreatment (Geriatric Depression Scale score improvement, 31%; 95% CI, 10% to 47%).<sup>7</sup>

The van Zon et al (2016) prospective study focused on tinnitus perception conducted as a part of a multicenter RCT comparing unilateral with bilateral cochlear implantation in patients who had severe bilateral sensorineural hearing loss.<sup>8</sup> This analysis included 38 adults enrolled from 2010 to 2012 and randomized to simultaneous bilateral or unilateral cochlear implants. At 1-year postimplantation, both unilaterally and bilaterally implanted patients had significant decreases in score on the Tinnitus Handicap Inventory (THI; a validated scale), with a change in score from 8 to 2 ( $p = .03$ ) and from 22 to 12 ( $p = .04$ ) for unilaterally and bilaterally implanted patients, respectively. Bilaterally implanted patients had a significant decrease in Tinnitus Questionnaire score (change in score, 20 to 9;  $p = .04$ ).

### Cochlear Implantation in Pediatrics

Similar to the adult population, the evidence related to the use of cochlear implants in children has been evaluated in several systematic reviews, technology assessments, and observational studies. The Bond et al (2009) technology assessment on cochlear implants made the following observations regarding cochlear implantation in children: All studies in children that compared 1 cochlear implant with nontechnologic support, or an acoustic hearing aid reported gains on all outcome measures.<sup>2</sup> Weak evidence showed greater gain from earlier implantation (before starting school).

In a review, Bond et al (2009) identified 15 studies that met their inclusion criteria addressing cochlear implantation in children; all were methodologically weak and too heterogeneous to perform a meta-analysis.<sup>9</sup> However, reviewers concluded that there was sufficient, consistent evidence demonstrating positive benefits with unilateral cochlear implants in severely to profoundly hearing-impaired children compared with acoustic hearing aids or no hearing support.

Baron et al (2018) published the results of a single-center, retrospective review of 109 children and adolescents who received a second, sequential cochlear implant between 2008 and 2016.<sup>10</sup> Inclusion criteria included  $< 20$  years at first cochlear implant, and minimum 12 years follow-up after second cochlear implant. Subjects were evaluated at baseline using tests for speech intelligibility and performance, auditory performance, and word and sentence recognition in silence and in noise. Patients were divided into 2 groups according to inter cochlear implant interval:  $< 3$  years (Early Group), versus  $\geq 3$  years (Late Group); and into 2 groups according to initial performance with the first cochlear implant: word recognition  $< 85\%$  (Weak Group), versus  $\geq 85\%$  (Strong Group). On the Categories of Auditory Performance (CAP) scale, 28.1% of patients showed improvement at 3 months

post-second cochlear implant, 47% at 12 months, and 51.9% at 24 months. Progression in CAP score between first cochlear implant and 3 months, 12 months, and 24 months post-second cochlear implant was significant ( $p < .05$ ). On the Speech Intelligibility Rating (SIR) scale, 33.7% of patients showed improvement at 3 months, 45.4% at 12 months, and 52.6% at 24 months ( $p < .05$ ). On word recognition, 47.4% of patients showed improvement at 3 months, 50.8% at 12 months, and 55% at 24 months ( $p < .05$ ). On sentence recognition in silence, 66.6% of patients showed improvement at 3 months, 61.2% at 12 months, and 60.6% at 24 months ( $p < .05$ ). Progression on sentence recognition in noise, on the other hand, was not significant ( $p = .55$ ). In the Early group, CAP score improved in 44.4% of patients at 3 months, 72.4% at 12 months and 76.1% at 24 months ( $p < .05$ ). In the Late group, progression was not significant at 3 months ( $p = 1$ ) or 12 months ( $p = .06$ ) but was significant at 24 months ( $p < .05$ ). In the Early group, SIR score improved in 49.1% of patients at 3 months, 63.0% at 12 months and 72.1% at 24 months. In the Late group, SIR score improved in 14.3% of patients at 3 months, 23.3% at 12 months, and 27.3% at 24 months. Improvement was significant in both groups at 3 months, 12 months, and 24 months ( $p < .05$ ). The following are some biases and limitations: (1) subjects' age advance over the study period. Audiometric and speech-therapy tests are age-adapted and were not necessarily the same at the various assessment time points; tests for older subjects are correspondingly more "difficult", so that speech therapy scores at 1-year post-second cochlear implant might be better than at 2 years, due to the nature of the respective tests. This biases assessment of individual progression over time. Patients were implanted between 1.2 and 24 years of age. Speech therapy tests at 3 months, 12 months, and 24 months thus differed between younger and older patients, introducing an inter-individual bias. (2) certain factors were not taken into account, like socioeconomic level, parental investment in the project, or associated behavioral, cognitive, psychomotor or sensory disorders, although these strongly impact cochlear implant results. They are, however, difficult to quantify, being subjective.

In March 2020, the U.S. Food and Drug Administration (FDA) approved to expand the indication for the Nucleus 24 Cochlear Implant System to include children aged 9 to 24 months of age who have bilateral profound sensorineural deafness and have demonstrated limited benefit from appropriate trials of binaural hearing aids.<sup>11</sup> Children 2 years of age and older may demonstrate severe to profound bilateral hearing loss. The approval was based on a retrospective analysis of prospective data from 5 centers in the United States in children aged between 9 and 12 months who were implanted between 2012 and 2017. Data were collected through March 2019 and included a total of 84 subjects (50% female). Average patient age was 10 months, 15 days and 61 subjects received bilateral implants. Post-operative follow up duration was 6 months. The most common adverse events observed were minor post operative complications (7.1%) and difficulties with temperature regulation during implantation (7.1%). Twenty-four patients experienced 28 medical/surgical complications and 26 of those complications were resolved without major surgical or medical intervention. Two reimplantation surgeries were reported. The benefits of the device for the age expansion from 12 to 9 months were based on a systematic review of the literature to support premarket approval. A literature search yielded 49 peer-reviewed studies that reported data on safety and/or effectiveness of implantation in children prior to 12 months of age reflecting data on 750 subjects. Significant benefits in terms of improved speech and language development are expected through expansion of the indication in children from 12 to 9 months as reflected by significant improvements in speech intelligibility rating and categorical auditory performance scores.<sup>12</sup> Older implanted children (12 to 29 months) demonstrated more delayed and atypical language abilities over time.<sup>13</sup> The study was limited by lack of effectiveness measures, failure to reach a minimum sample size of 100 patients, lack of a prespecified primary safety endpoint, and insufficient follow-up duration to capture long-term adverse events.

### Cochlear Implant Timing in Pediatrics

The optimal timing of cochlear implantation in children is of particular interest, given the strong associations between hearing and language development. As reported by Sharma and Dorman (2006), central auditory pathways are "maximally plastic" for about 3.5 years, making a case for earlier cochlear implantation of children with hearing impairment.<sup>14</sup> Stimulation delivered before

about 3.5 years of age results in auditory evoked potentials that reach normal values in 3 to 6 months.

Forli et al (2011) conducted a systematic review of 49 studies on cochlear implant effectiveness in children that addressed the impact of age of implantation on outcomes.<sup>15</sup> Heterogeneity of studies precluded meta-analysis. Early implantation was examined in 22 studies, but few studies compared outcomes of implantations performed before 1 year of age with implantations performed after 1 year of age. Studies suggested improvements in hearing and communicative outcomes in children receiving implants before 1 year of age, although it is uncertain whether these improvements were related to the duration of cochlear implant usage or age of implantation. However, reviewers noted hearing outcomes have been shown to be significantly inferior in patients implanted after 24 to 36 months. Finally, 7 studies were reviewed that examined cochlear implant outcomes in children with associated disabilities. In this population, cochlear implant outcomes were inferior and occurred more slowly but were considered to be beneficial.

As noted, the 1995 National Institutes of Health Consensus Development Conference concluded cochlear implants are recognized as an effective treatment of sensorineural deafness.<sup>1</sup> This conference offered the following conclusions regarding cochlear implantation in children:

- Cochlear implantation has variable results in children. Benefits are not realized immediately but rather manifest over time, with some children continuing to show improvement over several years
- Cochlear implants in children under 2 years old are complicated by the inability to perform detailed assessment of hearing and functional communication. However, a younger age of implantation may limit the negative consequences of auditory deprivation and may allow more efficient acquisition of speech and language. Some children with postmeningitis hearing loss under the age of 2 years have received an implant due to the risk of new bone formation associated with meningitis, which may preclude a cochlear implant at a later date.

Studies published since the systematic reviews above have suggested that cochlear implant removal and reimplantation (due to device malfunction or medical/surgical complications) in children is not associated with worsened hearing outcomes.<sup>16</sup>

### **Specific Indications for Cochlear Implantation in Pediatrics**

Several systematic reviews have evaluated outcomes after cochlear implantation for specific causes of deafness and in subgroups of pediatric patients. In 2011, a systematic review of 38 studies, Black et al sought to identify prognostic factors for cochlear implantation in pediatric patients.<sup>17</sup> A quantitative meta-analysis was not performed due to study heterogeneity. However, 4 prognostic factors— age at implantation, inner ear malformations, meningitis, and connexin 26 (a genetic cause of hearing loss) -- consistently influenced hearing outcomes.

Pakdaman et al (2012) conducted a systematic review of cochlear implants in children with cochleovestibular anomalies.<sup>18</sup> Anomalies included inner ear dysplasia such as large vestibular aqueduct and anomalous facial nerve anatomy. Twenty-two studies were reviewed (N=311). Reviewers found implantation surgery was more difficult and speech perception was poorer in patients with severe inner ear dysplasia. Heterogeneity across studies limited interpretation of these findings.

### **Auditory Neuropathy Spectrum Disorder**

In a systematic review, Fernandes et al (2015) evaluated 18 published studies and 2 dissertations that reported hearing performance outcomes for children with auditory neuropathy spectrum disorder (ANSD) and cochlear implants.<sup>19</sup> Studies included 4 nonrandomized controlled studies considered high quality, 5 RCTs considered low quality, and 10 clinical outcome studies. Most studies (n=14) compared the speech perception in children who had ANSD and cochlear implants to the speech

perception in children who had sensorineural hearing loss and cochlear implants. Most of these studies concluded that children with ANSD and cochlear implants developed hearing skills similar to those with sensorineural hearing loss and cochlear implants; however, these types of studies do not permit comparisons across outcomes between ANSD patients treated with cochlear implants and those treated with usual care.

Bo et al (2023) evaluated 15 studies to assess the effect of cochlear implantation on auditory and speech performance outcomes of children with ANSD.<sup>20</sup> The evidence suggested that children with ANSD who received cochlear implants appeared to achieve similar improvements in their auditory and speaking abilities as children with non-ANSD sensorineural hearing loss. According to pooled data, the categories of auditory performance, speech recognition score, speech intelligence rating score, and open-set speech perception did not significantly differ between the ANSD and sensorineural hearing loss groups.

### **Cochlear Implantation in Infants Younger Than 12 Months**

While currently available cochlear implants are labeled by the FDA for use in children older than 9 to 12 months of age, earlier diagnosis of congenital hearing loss with universal hearing screening has prompted interest in cochlear implantation in younger children.

Vlastarakos et al (2010) conducted a systematic review of studies on bilateral cochlear implantation in 125 children implanted before age 1 year.<sup>21</sup> For this off-label indication, reviewers noted follow-up times ranged from a median duration of 6 to 12 months and, while results seemed to indicate accelerated rates of improvement in implanted infants, the evidence available was limited and of poor quality.

A number of small studies from outside the United States have reported on cochlear implants in infants younger than 12 months old. For example, in a study from Australia, Ching et al (2009) published an interim report on early language outcomes among 16 children implanted before 12 months of age, compared with 23 who were implanted after 12 months of age (specific timing implantation was not provided).<sup>22</sup> The results demonstrated that children who received an implant before 12 months of age developed normal language skills at a rate comparable with normal-hearing children, while those implanted later performed at 2 standard deviations (SD) below normal. Reviewers noted that these results were preliminary, because of the need to examine the effect of multiple factors on language outcomes and the rate of language development.

Similarly, in a study from Italy, Colletti et al (2011) reported on 10-year results among 19 infants with cochlear implants received between the ages of 2 and 11 months (early implantation group) compared with 21 children implanted between the ages of 12 and 23 months and 33 children implanted between the ages of 24 and 35 months.<sup>23</sup> Within the first 6 months postimplantation, there were no significant differences among groups in CAP testing, but patients in the infant group had greater improvements than older children at the 12- and 36-month testing.

A more recent (2016) prospective study of 28 children with profound sensorineural hearing loss who were implanted early with cochlear implants (mean age at device activation, 13.3 months) reported that these children had social and conversational skills in the range of normal-hearing peers 1 year after device activation.<sup>24</sup>

### **Cochlear Implantation in Children: Bilateral Stimulation**

In a systematic review, Lammers et al (2014) compared the evidence on the effectiveness of bilateral cochlear implantation with that for unilateral implantation among children with sensorineural hearing loss.<sup>25</sup> Reviewers identified 21 studies that evaluated bilateral cochlear implantation in children, with no RCTs identified. Due to the limited number of studies, heterogeneity in outcomes and comparison groups, and high-risk for bias in the studies, reviewers could not perform pooled statistical analyses, so a best-evidence synthesis was performed. The best-evidence synthesis

demonstrated that there is consistent evidence indicating the benefit of bilateral implantation for sound localization. One study demonstrated improvements in language development, although other studies found no significant improvements. Reviewers noted that the currently available evidence consisted solely of cohort studies that compared a bilaterally implanted group with a unilaterally implanted control group, with only 1 study providing a clear description of matching techniques to reduce bias.

Several publications not included in the Lammers et al (2014) systematic review have evaluated bilateral cochlear implants in children. These studies, ranging in size from 91 to 961 patients, have generally reported improved speech outcomes with bilateral implantation compared with unilateral implantation.<sup>26,27,28,29</sup> In another retrospective case series (2013) of 73 children and adolescents who underwent sequential bilateral cochlear implantation with a long (>5 year) interval between implants, performance on the second implanted side was worse than the primary implanted side, with outcomes significantly associated with the interimplant interval.<sup>30</sup>

### **Section Summary: Cochlear Implantation for Bilateral Sensorineural Hearing Loss**

Multiple trials of cochlear implantation in patients with bilateral sensorineural hearing loss, although in varying patient populations, have consistently demonstrated improvements in speech recognition in noise and improved sound localization.

### **Cochlear Implantation for Unilateral Sensorineural Hearing Loss**

#### **Clinical Context and Therapy Purpose**

The purpose of cochlear implant(s) is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as best-aided hearing, in individuals with unilateral sensorineural hearing loss.

Contraindications to cochlear implantation may include deafness due to lesions of the eighth cranial (acoustic) nerve, central auditory pathway, or brainstem; active or chronic infections of the external or middle ear; and mastoid cavity or tympanic membrane perforation. Cochlear ossification may prevent electrode insertion, and the absence of cochlear development as demonstrated on computed tomography scans remains an absolute contraindication.

The following PICO was used to select literature to inform this review.

#### ***Populations***

The relevant population of interest are individuals with unilateral sensorineural hearing loss.

#### ***Interventions***

The therapy being considered is cochlear implant(s).

#### ***Comparators***

Comparators of interest include best-aided hearing.

#### ***Outcomes***

The general outcomes of interest are symptoms, functional outcomes, treatment-related mortality, and treatment-related morbidity.

The existing literature evaluating cochlear implant(s) as a treatment for unilateral sensorineural hearing loss has varying lengths of follow-up, ranging from 3 months to 6 months. While studies described below all reported at least one outcome of interest, longer follow-up was necessary to fully observe outcomes. Therefore, 6-months of follow-up is considered necessary to demonstrate efficacy.

### Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess longer-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

As noted, a number of potential benefits to binaural hearing exist, including binaural summation, which permits improved signal detection threshold, and sound localization. The potential benefits from binaural hearing have prompted interest in cochlear implantation for patients with unilateral hearing loss.

### Review of Evidence

#### Systematic Reviews

Oh et al (2022) published a systematic review and meta-analysis of 50 studies, including prospective and retrospective observational studies and case series, evaluating cochlear implantation in adults (n=674) with single-sided deafness.<sup>31</sup> Pooled outcomes indicated improved scores in speech perception (SMD, 2.8; 95% CI, 2.16 to 3.43; 7 studies;  $I^2=73.1\%$ ), localization (SMD, -1.13; 95% CI, -1.68 to -0.57; 7 studies;  $I^2=71.5\%$ ), tinnitus (SMD, -1.32; 95% CI, -1.85 to -0.80; 8 studies;  $I^2=73.1\%$ ); and quality of life (SMD, 0.61; 95% CI, 0.45 to 0.91; 10 studies;  $I^2=0.0\%$ ). Study interpretation is limited by small sample sizes and heterogeneity in reported outcomes and follow-up durations.

Benchetrit et al (2021) published a systematic review and meta-analysis evaluating audiological and patient-reported outcomes in children <18 years with single-sided deafness.<sup>32</sup> Twelve observational studies evaluating 119 children (mean age [SD], 6.6 [4.0] years) were included. Clinically meaningful improvements in speech perception in noise (39/49 [79.6%]) and in quiet (34/42 [81.0%]) were reported. Sound localization improved significantly following implantation (MD, -24.78°; 95% CI, -34.16° to -15.40°;  $I^2=10\%$ ). Compared to patients with congenital single-sided deafness, patients with acquired single-sided deafness and shorter duration of deafness reported greater improvements in speech and hearing quality. Patients with longer duration of deafness were also more likely to be device nonusers (MD, 6.84; 95% CI, 4.02 to 9.58).

#### Randomized Trials

Marx et al (2021) conducted a small open-label, multicenter RCT of cochlear implantation (n=25) versus initial observation and treatment abstention (n=26) in adult patients with single-sided deafness or asymmetric hearing loss following failure of prior treatment with contralateral routing of the signal (CROS) hearing aids or bone-conduction devices.<sup>33</sup> Primary outcomes included HRQOL, auditory-specific quality of life, and tinnitus severity as assessed after 6 months of treatment. Both EQ-5D visual analog scale and auditory-specific quality of life indices significantly improved in the cochlear implant arm. However, no significant difference in overall EQ-5D descriptive component scores were noted between groups. Mean improvement was most pronounced in subjects with associated severe tinnitus. A clinical rationale for the minimum clinical improvement in quality of life (0.8 SD) was not reported. No significant difference for speech recognition in noise or horizontal localization was noted between groups at 6 months, indicating no significant effect on binaural hearing within this timeframe.

Peters et al (2021) randomized 120 adults with single-sided deafness (median duration, 1.8 years) into 3 treatment groups for the "Cochlear Implantation for single-sided deafness" (CINGLE) trial: cochlear implant (n=29); first bone-conduction devices, then CROS (n=45); and first CROS, then bone-conduction devices (n=46).<sup>34</sup> Patients with a maximum 30 dB hearing loss in the best ear and a minimum 70 dB hearing loss in the poor ear with duration of single-sided deafness between 3

months and 10 years were eligible for inclusion. After the initial cross-over period, 25 patients were allocated to bone-conduction devices, 34 patients were allocated to CROS, and 26 patients preferred no treatment. Seven patients did not receive their allocated treatment. For the primary outcome, speech perception in noise from the front, a statistically significant improvement was noted for the cochlear implant group at 3 and 6 months compared to baseline. At 3 months follow-up, the cochlear implant group performed significantly better than all other groups. At 6 months, the cochlear implant group performed significantly better than the bone-conduction devices and no treatment groups but no significant difference was observed between the cochlear implant group and the CROS group. Sound localization improved in the cochlear implant group only. All treatment groups improved on disease-specific quality of life compared to baseline. The study is limited by small sample size, device heterogeneity, loss to follow-up, and lack of allocation concealment. Study follow-up through 5 years is ongoing.

### Nonrandomized Trials

Buss et al (2018) published the results of an FDA clinical trial that investigated the potential benefit of cochlear implant for use in adult patients with moderate-to-profound unilateral sensorineural hearing loss and normal to near-normal hearing on the other side.<sup>35</sup> The study population was 20 cochlear implant recipients with one normal or near-normal ear and the other met criterion for cochlear implantation. All subjects received a MED-EL standard electrode array, with a full insertion based on surgeon report. They were fitted with an OPUS 2 speech processor. This group was compared to 20 normal-hearing persons (control group) that were age-matched. Outcome measures included: sound localization on the horizontal plane; word recognition in quiet with the cochlear implant alone, and masked sentence recognition when the masker was presented to the front or the side of normal or near-normal hearing. The follow-up period was 12 months. While the majority of cochlear implant recipients had at least 1 threshold  $\leq 80$  dB prior to implantation, only 3 subjects had these thresholds after surgery. For cochlear implant recipients, scores on consonant-nucleus-consonant words in quiet in the impaired ear rose an average of 4% (0% to 24%) at the postoperative test to a mean of 55% correct (10% to 84%) with the cochlear implant alone at the 12-month test interval.

Dillon et al (2019) published a clinical update reporting on the prevalence of low-frequency hearing preservation with the use of standard long electrode arrays (MED-EL Corporation) in a subset of 25 patients (12 with unilateral hearing loss) from earlier cohorts.<sup>36</sup> Unaided hearing thresholds at 125 Hz were compared between the preoperative and initial activation intervals to assess the change in low-frequency hearing. At activation, a significant elevation in the unaided hearing thresholds at 125 Hz was noted among a sample of 24 patients ( $p < .001$ ), with the majority of subjects ( $n = 16$ ) demonstrating no response to stimulus. The remaining 9 participants maintained an unaided low-frequency hearing threshold of  $\leq 95$  dB, and 5/9 participants met the fitting criterion of  $\leq 80$  dB for electric-acoustic stimulation at initial activation. An additional 3 participants demonstrated improvement in unaided low-frequency hearing thresholds at latter monitoring intervals. It is uncertain whether identifying patients with preservation of low-frequency hearing can help predict individuals that may benefit from electric-acoustic stimulation versus standard cochlear implants.

Galvin III et al (2019) reported data from an FDA-approved study of cochlear implantation in 10 patients with single-sided deafness.<sup>37</sup> Patients were implanted with the MED-EL Concerto Flex 28 device. Speech perception in quiet and noise, localization, and tinnitus severity were measured prior to implantation at 1, 3, and 6 months postactivation. Performance was assessed with both ears (binaural), with the implanted ear alone, and the normal hearing alone. No patient had previous experience with contralateral routing of signal or bone conduction device system. Mean improvement for consonant-nucleus-consonant word recognition versus baseline was 66.8%, 76.0%, and 84.0% at 1, 3, and 6 months postactivation, respectively. The normal hearing ear performed significantly better compared to the implanted ear for all outcome measures at all intervals ( $p < .05$ ). Audiological performance of the implanted ear at 1, 3, and 6 months postactivation was significantly better compared to baseline ( $p < .05$ ), with no significant difference across postactivation intervals



( $p > .05$ ). The change in root mean square error in localization with binaural listening postactivation reduced by 6.7, 7.6, and 11.5 degrees at 1, 3, and 6 months postactivation. Binaural performance was significantly improved compared to the normal hearing ear alone at all postactivation time intervals ( $p < .05$ ). Tinnitus visual analog scale scores significantly decreased with the implant on at all postactivation time intervals ( $p < .05$ ). Significant improvements in Speech, Spatial, and Qualities of Hearing Scale questionnaire (SSQ) scores were reported for the Speech ( $p = .003$ ), Spatial ( $p < .001$ ), and Quality ( $p = .034$ ) subtests. Global scores were not reported. Adverse events were reported in 5/10 participants, including facial nerve stimulation, periorbital edema, mild postoperative balance disturbance, postauricular pain, and unresolved taste disturbance. The study is limited by small sample size.

Peter et al (2019) published the results of a Swiss multicenter study assessing cochlear implantation for use in adult patients in post-lingual single-sided deafness, defined as a hearing loss of 70 dB hearing level in the mean thresholds of 0.5, 1, 2, and 4 kHz in the affected ear, and 25 dB hearing level or better in the frequencies from 125 to 2 kHz and 35 dB hearing level or better from 4 to 8 kHz in the normally hearing contralateral ear.<sup>38</sup> A total of 10 patients were evaluated. Two years post-implantation, 90% of patients used their implant regularly for an average of more than 11 hours per day. Twelve months postactivation, speech from the front and noise at the healthy ear achieved a 2.7 dB improvement ( $p = .0029$ ). Speech to the implanted ear and noise from the front achieved a 1.5 dB improvement ( $p = .018$ ). The mean sound localization error of all participants was improved by 10.2 degrees ( $p = .030$ ) at 12 months postactivation. One participant experienced a loss in low-frequency residual hearing from surgery, resulting in poorer localization performance after surgery with an increased error of 11.3 degrees. Tinnitus severity decreased significantly 12 months postactivation from 41.2 points (SD, 26.5) preoperatively to 23.0 points (SD, 17.5;  $p = .004$ ) on the Tinnitus Handicap Inventory (THI). Quality of life measures showed a significant improvement on the global subscale of the World Health Organization quality of life questionnaire ( $p = .007$ ). The SSQ indicated a significant improvement from 4.2 to 6 ( $p = .004$ ) in speech comprehension and from 3 to 5.3 ( $p = .009$ ) in spatial hearing. No significant difference was noted in the subscale qualities of hearing (6.2 to 6.9;  $p = .13$ ). The scores on the 3 subscales were significantly lower than for the normal hearing control group, with an average speech comprehension score of 8.7 ( $p = .001$ ), an average spatial hearing of 8.6 ( $p < .001$ ), and an average quality of hearing score of 9.1 ( $p = .005$ ). Adverse events were not reported.

Poncet-Wallet et al (2019) reported on audiological and tinnitus outcomes of cochlear implantation in adults with single-sided deafness and tinnitus.<sup>39</sup> Twenty-six patients with single-sided deafness and incapacitating tinnitus (THI score  $> 58$ ) underwent cochlear implantation. Masking white noise stimulation was delivered for the first month post implantation, after which standard cochlear implant stimulation was provided. Catastrophic handicaps (grade 5, THI 78 to 100) were noted for 31% of participants and severe handicaps (grade 4, THI 58 to 76) were noted for 69% of participants. The first month of white noise stimulation provided a significant improvement in THI scores ( $72 \pm 9$  to  $55 \pm 20$ ;  $p < .05$ ). No change was observed for the other measures at this time point. After 1 year of standard stimulation, 23 patients (92%) completed the final 13-month visit with 0% of participants reporting catastrophic handicaps, 4% reporting severe handicaps, and 26% reporting moderate handicaps (grade 3, THI 38 to 56), 30% reporting mild handicaps (grade 2, THI 18 to 36), and 39% reporting slight or no handicaps (grade 1, THI 0 to 16) ( $p < .05$ ). All 23 patients attending the 13-month visit reported improvement of tinnitus on at least 2 of 4 tinnitus questionnaires.

Dillon et al (2020) conducted a prospective clinical trial evaluating 20 subjects with asymmetric hearing loss, defined as a hearing loss of  $\geq 70$  dB hearing level in the ear to be implanted and between 35 and 55 dB hearing level in the contralateral ear.<sup>40</sup> Patients were required to fail initial treatment with traditional or bone-conduction hearing aids. Subjects underwent cochlear implantation with the MED-EL Synchrony Standard electrode array. Significant subjective benefit was reported by patients within 1 month of implantation. At the 12-month interval, spatial hearing localization was significantly improved ( $p < .001$ ). Masked sentence recognition was found to improve at the 12-month interval in the sound from 90 degrees to the contralateral ear configuration ( $p < .001$ ),

but there was no significant difference in the sound from the front or from 90 degrees to the cochlear implant ear spatial configurations. Subjects demonstrated a significant improvement in consonant-nucleus-consonant word recognition between 1 and 6 months ( $p<.002$ ) and 6 and 12 months ( $p=.10$ ). Findings were compared with previously published data for patients in the unilateral hearing loss cohort of this study.<sup>35</sup> Significant main effects of cohort were found for localization performance and spatial configuration in masked sentence recognition, indicating that the magnitude of benefit for these outcomes was reduced for subjects with asymmetric hearing loss.<sup>40</sup>

In July 2019, the FDA approved to expand the indication for the MED-EL Cochlear Implant System to include individuals aged 5 years and older with single-sided deafness or asymmetric hearing loss.<sup>41</sup> According to the FDA's summary of safety and effectiveness data, approval was based on supporting evidence from a comprehensive literature review and a clinical feasibility study conducted at the University of North Carolina at Chapel Hill under IDE# G140050 in patients treated between 2014 and 2019. In this prospective, non-blinded, repeated measures study, 40 subjects were implanted with the MED-EL CONCERT or SYNCHRONY Cochlear Implant System. Twenty patients each were enrolled into the single-sided deafness and asymmetric hearing loss groups. All 20 patients completed testing in the single-sided deafness group. One patient withdrew from the asymmetric hearing loss group and 1 patient had not yet completed follow-up at the time of data analysis. Patients were required to have previous experience of at least 1 month in duration with a conventional hearing aid, bone conduction device, or CROS device. Exclusion criteria included Meniere's disease with intractable vertigo, tinnitus as the primary concern for cochlear implantation, and severe or catastrophic score on the THI. Aided word recognition in the ear to be implanted was required to be 60% or less as measured with a 50-word consonant-nucleus-consonant word list. Speech perception and localization were evaluated at baseline and at 1, 3, 6, 9, and 12 months post operatively utilizing consonant-nucleus-consonant word recognition and AzBio sentence tests. For patients in the asymmetric hearing loss group, sound field testing was completed with a hearing aid in the contralateral ear. Quality of life measures included the SSQ, THI, and Abbreviated Profile of Hearing Aid Benefit (APHAB) scales. Primary effectiveness measures were comparisons of speech perception and localization performance between the bilateral, pre operative, unaided/best-aided condition and the bilateral, 12-month post operative cochlear implant plus normal hearing or hearing aid condition. Study results are summarized in Table 2. Nine device- or procedure-related adverse events were reported. Most frequently reported adverse events included vertigo/dizziness/imbalance (22.5%) and unrelated infection (7.5%). The data from the study is limited by its small sample size in adult subjects only. Effectiveness endpoints were not prespecified.

The FDA decision was further supported by a literature search yielding 6 publications comprising a total of 58 adults with single-sided deafness ( $n=50$  were implanted with MED-EL devices) and a total of 52 adults with asymmetric hearing loss ( $n=37$  were implanted with MED-EL devices). The decision to expand the indication to pediatric patients aged 5 and older was based on a literature search yielding 5 publications comprising a total of 26 children with single-sided deafness ( $n=5$  were implanted with a MED-EL device) and a total of 9 children with asymmetric hearing loss. While the overall benefits of cochlear implants in children with single-sided deafness and asymmetric hearing loss included improved performance in speech perception in quiet and noise, sound localization, and subjective measures of quality of life, these results are limited to primarily case series with small sample sizes, heterogeneous methodology and outcome assessment, and high risk of bias in self-reported measures. The FDA has required MED-EL to conduct a postmarketing study to continue to assess the safety and efficacy of the implant in a new enrollment cohort of adults and children.<sup>42</sup>

**Table 2. Feasibility Study Results for MED-EL Cochlear Implant System for Single-sided Deafness and Asymmetric Hearing Loss<sup>41</sup>**

Outcome	SSD (n=20)			AHL (n=18)		
	Baseline, Unaided	12-mo, Unaided	12-mo, CI-On	Baseline, Unaided	12-mo, Unaided	12-mo, CI-On
Speech Perception in Quiet						

Outcome	SSD (n=20)			AHL (n=18)		
Implant Ear CNC, Mean (SD) Range	3.5 (6.68) 0 to 22	NA	54.6 (18.15) 10 to 84	6.3 (7.98) 0 to 22	NA	56.2 (18.41) 28 to 86
Contralateral Ear CNC, Mean (SD) Range	99.3 (2.27) 90 to 100	99.8 (0.62) 98 to 100	NA	92.7 (8.68) 78 to 100	92.7 (8.68) 72 to 100	NA
Soundfield, Binaural AzBio, Mean (SD) Range	99.0 (1.56) 95 to 100	NA	99.5 (1.19) 95 to 100	87.4 (13.96) 50 to 99	NA	94.3 (8.38) 72 to 100
	SSD (N=20)			AHL (N=17)		
Speech Perception in Noise Noise Front AzBio, Mean (SD) Range	Baseline, Unaided	Baseline, Best-Aided (BCHA)	12-mo, CI-On	Baseline, Unaided	Baseline, Best-Aided (BCHA)	12-mo, CI-On
	37.5 (10.98) 20 to 64	31.5 (16.56) 0 to 59	47.2 (10.72) 29 to 68	22.7 (13.95) 0 to 47	20.5 (12.86) 0 to 47	33.5 (22.10) 3 to 85
Noise at CI AzBio, Mean (SD) Range	83.4 (9.51) 59 to 94	61.25 (27.92) 0 to 98	85.0 (11.04) 60 to 97	44.2 (17.70) 9 to 78	30.5 (18.23) 1 to 70	44.6 (24.74) 5 to 94
Noise at Contralateral AzBio, Mean (SD) Range	16.5 (12.78) 0 to 45	18.3 (13.50) 0 to 59	52.6 (21.43) 8 to 86	6.3 (9.49) 0 to 36	11.3 (16.69) 0 to 66	29.4 (22.59) 1 to 95
	SSD (N=20)			AHL (N=18)		
Localization Performance Mean RMS Error (SD) Range	Baseline, Unaided	Baseline, Best-Aided (BCHA)	12-mo, CI-On	Baseline, Unaided	Baseline, Best-Aided (BCHA)	12-mo, CI-On
	66.5 (20.47) 42.9 to 109.1	69.6 (18.71) 45.3 to 106.1	26.7 (6.32) 13.6 to 38.4	76.5 (19.23) 43.8 to 105.3	77.2 (18.89) 45.6 to 106.5	40.1 (10.65) 26.6 to 73.6
Quality of Life	SSQ (Speech)	SSQ (Spatial)	SSQ (Qualities)	APHAB (Global)	APHAB (EC, RV, BN, AV)	THI
SSD (N=20) Baseline: Mean (SD); Range 12-mo: Mean (SD); Range	3.7 (1.34); 0.6 to 7.2 7.1 (0.99); 5.4 to 8.9	2.4 (1.2); 0.5 to 4.5 6.5 (1.86); 2.8 to 8.9	5.6 (2.09); 0.5 to 9.8 7.7 (1.28); 5.6 to 9.8	49.8 (18.65); 20.3 to 86.3 17.9 (8.91); 6.1 to 36.7	EC: 31.6 (21.06); 2.8 to 81.0 8.7 (6.15); 1.0 to 24.8 BN: 70.1 (17.32); 39.3 to 95.0 25.2 (11.95); 10.2 to 56.2 RV: 47.5 (21.96); 18.7 to 87.0 19.7 (12.43); 2.8 to 41.7 AV: 43.1 (28.64); 1.0 to 93.0 26.7 (24.83); 1.0 to 91.0	NR

Outcome	SSD (n=20)			AHL (n=18)		
AHL (N=18)	3.2 (1.48); 0.4	2.6 (1.26); 0.3	4.6 (1.77); 0.2 to	54.1 (16.21);	EC:	NR
Baseline: Mean	to 6.0	to 4.7	8.3	20.0 to 92.3	42.9 (24.67);	
(SD); Range	5.8 (1.50); 3.6	6.0 (1.62); 3.1	6.8 (1.20); 4.4 to	28.1 (10.49);	10.2 to 91.0	
12-mo: Mean	to 8.9	to 8.5	8.7	11.3 to 54.1	16.6 (13.01); 1.0	
(SD); Range					to 54.0	
					BN:	
					63.5 (16.84);	
					14.5 to 95.0	
					39.3 (17.10);	
					14.5 to 66.3	
					RV:	
					56.0 (18.30);	
					14.2 to 97.0	
					28.3 (11.96);	
					12.0 to 54.2	
					AV:	
					43.1 (35.04);	
					1.0 to 99.0	
					42.4 (29.21); 1.0	
					to 97.0	

AHL: asymmetric hearing loss; APHAB: Abbreviated Profile of Hearing Aid Benefit; AV: Aversiveness subscale; BCHA: bone conduction hearing aid; BN: Background Noise subscale; CI: cochlear implant; CNC: consonant-nucleus-consonant; EC: Ease of Communication subscale; NA: not applicable; NR: not reported; RMS: root mean square; RV: Reverberation subscale; SD: standard deviation; SSD: single-sided deafness; SSQ: Speech, Spatial, and Qualities of Hearing Scale; THI: Tinnitus Handicap Inventory.

In January 2022, the FDA approved to expand the indication for the Nucleus 24 Cochlear Implant System to individuals aged 5 years and older with single-sided deafness or asymmetrical hearing loss.<sup>43</sup> According to the FDA's summary of safety and effectiveness data, approval was based on unpublished data in 42 adults from a feasibility study (n=10) and real-world data from two cochlear implantation centers (n=32). Study interpretation is limited by small sample size in adult subjects only, unclear rationale for the efficacy threshold, and missing data. The FDA has required Cochlear Americas to conduct a postmarketing study to continue to assess the safety and efficacy of the implant in a new enrollment cohort of adults and children.

### Cochlear Implant for Tinnitus Relief in Patients with Unilateral Deafness

Based on observations about tinnitus improvement with cochlear implants, several studies have reported on improvements in tinnitus after cochlear implantation in individuals with unilateral hearing loss. For example, in the meta-analysis by Vlastarakos et al (2014), tinnitus improved in most patients (95%).<sup>44</sup>

Ramos Macias et al (2015) reported on results of a prospective multicenter study with repeated measures related to tinnitus, hearing, and quality of life, among 16 individuals with unilateral hearing loss and severe tinnitus who underwent cochlear implantation.<sup>45</sup> All patients had a severe tinnitus handicap (THI score  $\geq 58\%$ ). Eight (62%) of the 13 patients who completed the 6-month follow-up visit reported a lower tinnitus handicap on the THI score. Perceived loudness/annoyingness of the tinnitus was evaluated with a 10-point visual analog scale. Tinnitus loudness decreased from 8.4 preoperatively to 2.6 at the 6-month follow-up.

Tavora-Vieira et al (2013) reported on results of a prospective case series that included 9 postlingually deaf subjects with unilateral hearing loss, with or without tinnitus in the ipsilateral ear, with functional hearing in the contralateral ear, who underwent cochlear implantation.<sup>46</sup> Speech perception was improved for all subjects in the "cochlear implant on" state compared with the "cochlear implant off" state, and subjects with tinnitus generally reported improvement.

### **Cochlear Implantation in Pediatric Population with Unilateral Deafness**

Brown et al (2022) published results from the Childhood Unilateral Hearing Loss (CUHL) prospective, single-arm trial.<sup>47</sup> Twenty children aged 3-12 with moderate to profound sensorineural hearing loss and poor speech perception (word score <30%) in one ear and normal hearing in the contralateral ear were enrolled. CNC word score perception in quiet improved significantly from 1% to 50% ( $p<.0001$ ) at 12 months after activation. Speech perception in noise by BKB-SIN score also significantly improved by 3.6 dB in head shadow ( $p<.0001$ ), 1.6 dB in summation ( $p=.003$ ), and 2.5 dB in squelch ( $p=.0001$ ). By 9 months, localization improved by 26°. Significant improvements were also found in SSQ speech ( $p=.0012$ ), qualities of hearing ( $p=.0056$ ), and spatial hearing subscales ( $p<.0001$ ). Improvements in fatigue were not statistically significant. Study limitations include use of a single-arm study design, small sample size, and incomplete comparison to best-aided hearing at baseline, including enrollment of never aided subjects.

### **Section Summary: Cochlear Implantation for Unilateral Sensorineural Hearing Loss**

The available evidence for the use of cochlear implants in improving outcomes for individuals with unilateral hearing loss, with or without tinnitus, is limited by small sample sizes and heterogeneity in evaluation protocols and outcome measurements. A small feasibility study in adults with single-sided deafness or asymmetric hearing loss demonstrated improvements in sound perception, sound localization, and subjective measures of quality of life compared to baseline conditions. However, studies assessing outcomes compared to best-aided hearing controls beyond 6 months are lacking. Ongoing postmarketing studies in adults and children may further elucidate outcomes.

### **Hybrid Cochlear Implantation for Individuals with High-Frequency Sensorineural Hearing Loss With Preserved Low-Frequency Hearing**

#### **Clinical Context and Therapy Purpose**

The purpose of a hybrid cochlear implant that includes a hearing aid integrated into the external sound processor of the cochlear implant is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as best-aided hearing, in individuals with high-frequency sensorineural hearing loss with preserved low-frequency hearing.

The following PICO was used to select literature to inform this review.

#### ***Populations***

The relevant population of interest are individuals with high-frequency sensorineural hearing loss with preserved low-frequency hearing.

#### ***Interventions***

The therapy being considered is a hybrid cochlear implant that includes a hearing aid integrated into the external sound processor of the cochlear implant.

#### ***Comparators***

Comparators of interest include best-aided hearing.

#### ***Outcomes***

The general outcomes of interest are symptoms, functional outcomes, treatment-related mortality, and treatment-related morbidity.

#### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.

- To assess longer-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

## Review of Evidence

### Nonrandomized Trials

A concern about traditional cochlear implants is that the implantation process typically destroys any residual hearing, particularly for hearing in the low-frequency ranges. Newer devices have used a shorter cochlear electrode in combination with a hearing aid-like amplification device to mitigate the damage to the cochlea and preserve residual hearing.

In September 2016, the FDA approved the MED-EL Cochlear Implant with Combined Electrical Stimulation and Acoustic Amplification System (EAS) for partially deaf individuals aged 18 years and older who have residual hearing sensitivity in the low frequencies sloping to severe/profound sensorineural hearing loss in the mid- to high-frequencies, and who receive minimal benefit from conventional acoustic amplification. Final outcomes were reported in 2018 by Pillsbury et al.<sup>48</sup> Sixty-seven of 73 subjects (92%) completed outcome measures at 3, 6, and 12 months postactivation. A 30 dB or less low-frequency pure-tone average shift was experienced by 79% and 97% were able to use the acoustic unit at 12 months postactivation. In the EAS condition, 94% of subjects performed similarly or demonstrated improvement (85%) compared to preoperative performance on City University of New York sentences in noise at 12 months. Ninety-seven percent of subjects performed similarly or improved (85%) on consonant-nucleus-consonant words in quiet. Improvements in speech perception scores were statistically significant ( $p < .001$ ). The APHAB was administered preoperatively and at 12 months postactivation; 60 subjects completed the APHAB assessment at each time point. The mean score on the APHAB Global Scale improved by 30.2%, demonstrating a significant reduction in perceived disability ( $p < .001$ ). Thirty-five device-related adverse events were reported for 29 of 73 subjects (39.7%). The most frequently observed adverse event was profound/total loss of residual hearing, which occurred in 8 of 73 subjects (11.0%).

In March 2014, the FDA approved the Nucleus Hybrid L24 Cochlear Implant System for use through the premarket approval process. According to the FDA's summary of safety and effectiveness data, approval was based on 2 clinical studies conducted outside of the United States and a pivotal study of the Hybrid L24 device conducted under investigational device exemption.<sup>49</sup>

The pivotal trial was a prospective, multicenter, single-arm, nonrandomized, nonblinded, repeated measures clinical study among 50 subjects  $\geq 18$  years of age at 10 U.S. sites. Results were reported in FDA documentation and peer-reviewed form by Roland et al (2016).<sup>50</sup> Eligible patients were selected on the basis of having severe high-frequency sensorineural hearing loss ( $\geq 70$  dB hearing level averaged over 2000, 3000, and 4000 Hz) with relatively good low-frequency hearing ( $\leq 60$  dB hearing level averaged over 125, 250, and 500 Hz) in the ear selected for implantation. The performance was compared pre- and post implant within each subject; outcomes were measured at 3, 6, and 12 months postoperatively. The trial tested 2 coprimary efficacy hypotheses: (1) that outcomes on consonant-nucleus-consonant, a measure of word recognition, and (2) AzBio sentences in noise presented through the hybrid implant system would be better at 6 months post implantation than preoperative performance using a hearing aid.

All 50 subjects enrolled underwent device implantation and activation. One subject had the device explanted and replaced with a standard cochlear implant between the 3- and 6-month follow-up visit due to profound loss of low-frequency hearing; an additional subject was explanted before the 12-month follow-up visit, and 2 other subjects were explanted after 12 months. For the 2 primary effectiveness endpoints (consonant-nucleus-consonant word recognition score, AzBio sentence-in-noise score), there were significant within-subject improvements from baseline to 6-month follow-up. Mean improvement in consonant-nucleus-consonant word score was 35.8% (95% CI, 27.8% to 43.6%); for AzBio score, mean improvement was 32.0% (95% CI, 23.6% to 40.4%). Ninety-six percent of

subjects performed equal or better on speech in quiet and 90% performed equal or better in noise. For safety outcomes, 65 adverse events were reported, most commonly profound/total loss of hearing (occurring in 44% of subjects) with at least 1 adverse event occurring in 34 subjects (68%). Five-year outcomes for the pivotal trial were reported by Roland et al (2018).<sup>51</sup> Thirty-two of 50 subjects (64%) enrolled in the postapproval study. Out of the 18 subjects who did not participate, 6 had been explanted and reimplanted with a long electrode array, 2 discontinued for unrelated medical reasons, 2 withdrew for other reasons, 4 declined to continue follow-up evaluations, and 4 chose not to participate in the postapproval study. At 5 years postactivation, 94% of subjects had measurable hearing and 72% continued to use electric-acoustic stimulation with functional hearing in the implanted ear, and 6% had a total loss. Changes from pre operate hearing to 6 months were statistically significant ( $p < .001$ ), but changes 6 months through 5 years postactivation were not statistically different ( $p > .05$ ). Acoustic component amplification was utilized by 84% and 81% of patients at 12 and 3 years postactivation, respectively. Mean consonant-nucleus-consonant word recognition in quiet scores were significantly improved over the preoperative condition at each postactivation interval ( $p < .001$ ). However, mean scores did not significantly differ after 12 months postactivation. At 5 years postactivation, 94% performed the same or better in unilateral consonant-nucleus-consonant word scores, whereas 6% demonstrated a decline in performance. For bilateral consonant-nucleus-consonant word scores, 97% performed the same or better, whereas 1 subject showed a decline in performance. The SSQ was implemented to measure subjective implant satisfaction and benefit. Scores significantly improved and remained stable through all postactivation intervals ( $p < .001$ ).

Lenarz et al (2013) reported on results of a prospective multicenter European study evaluating the Nucleus Hybrid L24 system.<sup>52</sup> The study enrolled 66 adults with bilateral severe-to-profound high-frequency hearing loss. At 1 year postoperatively, 65% of subjects had significant gains in speech recognition in quiet, and 73% had significant gains in noisy environments. Compared with the cochlear implant hearing alone, residual hearing significantly increased speech recognition scores.

#### **Hearing Benefit with Shorter Cochlear Array**

The Nucleus Hybrid L24 system was designed with a shorter cochlear implant with the intent of preserving low-frequency hearing. A relevant question is whether a shorter implant is associated with differences in outcomes, although studies addressing this question do not directly provide evidence about hybrid implants themselves.

Santa Maria et al (2014) published a meta-analysis of hearing outcomes after various types of hearing preservation cochlear implantation, which included implantation of hybrid devices, cochlear implantation with surgical techniques designed to preserve hearing, and the use of postoperative systemic steroids.<sup>53</sup> Reviewers included 24 studies, but only 2 focused specifically on a hybrid cochlear implant system, and no specific benefit from a hybrid system was reported.

Causon et al (2015) evaluated factors associated with cochlear implant outcomes in a meta-analysis of articles published from 2003 to 2013, which reported on pure-tone audiometry measurements pre- and post cochlear implantation.<sup>54</sup> Twelve studies with available audiometric data (N=200 patients) were included. Reviewers standardized degree of hearing preservation after cochlear implant using the HEARRING consensus statement formula. This formula calculates a percentage of hearing preservation at a specific frequency band, which is scaled to the preoperative audiogram by dividing the change in hearing by the difference between the maximum measurable threshold and the preoperative hearing threshold. The association of a variety of patient- and surgery-related factors, including insertion depth, and improvement in low-frequency hearing were evaluated. In this analysis, insertion depth was not significantly associated with low-frequency residual hearing.

Since the publication of the Santa Maria et al (2014) and Causon et al (2015) studies, which evaluated factors associated with cochlear implant outcomes, additional studies have attempted to evaluate whether shorter cochlear arrays are more likely to preserve hearing.

Gantz et al (2016) published outcomes from a multicenter, longitudinal study evaluating outcomes with the Nucleus Hybrid S8 featuring a shorter cochlear array.<sup>55</sup> Eighty-seven subjects received an implant. At 12 months postactivation, 5 subjects had total hearing loss, whereas functional hearing was maintained by 80%. Consonant-nucleus-consonant word scores demonstrated that 82.5% of subjects had experienced a significant improvement in the hybrid condition. Improvement in speech understanding in noise were demonstrated in 55% of subjects. Fourteen patients requested implant explantation due to various reasons for dissatisfaction with the device. These patients were re-implanted with a standard length Nucleus Freedom cochlear implant. Consonant-nucleus-consonant scores prior to loss of residual hearing were missing for 6 subjects. Consonant-nucleus-consonant scores following re-implantation were missing for 2 additional subjects. Similar or better consonant-nucleus-consonant scores following re-implantation were observed in 5/6 remaining subjects.

### **Section Summary: Hybrid Cochlear Implantation**

Prospective and retrospective studies using a single-arm, within-subjects comparison pre- and postintervention have suggested that a hybrid cochlear implant system is associated with improvements in hearing of speech in quiet and noise. For patients who have high-frequency hearing loss but preserved low-frequency hearing, the available evidence has suggested that a hybrid cochlear implant improves speech recognition better than a hearing aid alone. Some studies have suggested that a shorter cochlear implant insertion depth may be associated with preserved residual low-frequency hearing, although there is uncertainty about the potential need for reoperation following hybrid cochlear implantation if there is a loss of residual hearing. Studies reporting on long-term outcomes and results of re-implantation are lacking.

### **Supplemental Information**

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

### **Clinical Input from Physician Specialty Societies and Academic Medical Centers**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

### **2016 Input**

In response to requests, input was received from 2 specialty societies, 1 of which provided 4 responses and 1 of which provided 3 responses, and 3 academic medical centers while this policy was under review in 2016. Input focused on the use of hybrid cochlear implants. Input was consistent that the use of a hybrid cochlear implant/hearing aid device that includes the hearing aid integrated into the external sound processor of the cochlear implant improves outcomes for patients with high-frequency hearing loss but preserved low-frequency hearing.

### **2010 Input**

In response to requests, input was received from 2 physician specialty societies and 4 academic medical centers while this policy was under review in 2010. Also, unsolicited input was received from a specialty society. Most providing input supported the use of cochlear implants in infants younger than 12 months of age; many supporting this use noted that there are major issues when determining the hearing level in infants of this age group, and others commented that use could be considered in these young infants only in certain situations. Those providing input were divided on the medical necessity of upgrading functioning external systems - some agreed, and others did not.

### **Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to



guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

### **American Academy of Otolaryngology - Head and Neck Surgery Foundation**

In 2020, the American Academy of Otolaryngology - Head and Neck Surgery Foundation released an updated position statement on cochlear implants.<sup>56</sup> The Foundation "...considers unilateral and bilateral cochlear implantation as appropriate treatment for adults and children over 9 months of age with moderate to profound hearing loss who have failed a trial with appropriately fit hearing aids."

### **Agency for Health Care Research and Quality**

In 2011, a technology assessment for the Agency for Health Care Research and Quality assessed the effectiveness of cochlear implants in adults.<sup>57</sup> The assessment conclusions are noted within the body of this evidence review.

### **National Institute for Health and Care Excellence**

In 2019, the NICE released a technology appraisal guidance on cochlear implants for children and adults with severe-to-profound deafness.<sup>58</sup>

The guidance included the following updated recommendations:

1.1 "Unilateral cochlear implantation is recommended as an option for people with severe to profound deafness who do not receive adequate benefit from acoustic hearing aids, as defined in 1.5.

1.2 Simultaneous bilateral cochlear implantation is recommended as an option for the following groups of people with severe to profound deafness who do not receive adequate benefit from acoustic hearing aids.

a. Children

b. Adults who are blind or who have other disabilities that increase their reliance on auditory stimuli as a primary sensory mechanism for spatial awareness.

1.3 Sequential bilateral cochlear implantation is not recommended as an option for people with severe to profound deafness.

1.5 For the purposes of this guidance, severe to profound deafness is defined as hearing only sounds that are louder than 80 dB HL [hearing level] at 2 or more frequencies bilaterally (500 Hz, 1 kHz, 2 kHz, 3 kHz, 4 kHz) without acoustic hearing aids. Adequate benefit from acoustic hearing aids is defined for this guidance as:

a. for adults, a phoneme score of 50% or greater on the Arthur Boothroyd word test presented at 70 dBA

b. for children, speech, language and listening skills appropriate to age, developmental stage, and cognitive ability.

1.6 Cochlear implantation should be considered for children and adults only after an assessment by a multidisciplinary team. As part of the assessment, children and adults should also have had a valid trial of an acoustic hearing aid for at least 3 months (unless contraindicated or inappropriate)."

1.7 Cochlear implantation should be considered for ... adults only after an assessment by a multidisciplinary team. As part of the assessment ... [implant candidates] should also have had a valid trial of an acoustic hearing aid for at least 3 months (unless contraindicated or inappropriate)."

### **National Institutes of Health**

Cochlear implants are recognized as an effective treatment of sensorineural deafness, as noted in a 1995 National Institutes of Health Consensus Development conference, which offered the following conclusions<sup>1</sup>:

- "Cochlear implantation has a profound impact on hearing and speech perception in postlingually deafened adults."
- "Prelingually deafened adults generally show little improvement in speech perception scores after cochlear implantation, but many of these individuals derive satisfaction from hearing

environmental sounds and continue to use their implants.” However, improvements in other basic benefits, such as sound awareness, may meet safety needs.

- “...training and educational intervention are fundamental for optimal postimplant benefit.”

The conference offered the following conclusions regarding cochlear implantation in children:

- “Cochlear implantation outcomes are more variable in children. Nonetheless, gradual, steady improvement in speech perception, speech production, and language does occur.”

Cochlear implants in children under 2 years old are complicated by the inability to perform a detailed assessment of hearing and functional communication. However, “[a] younger age of implantation may limit the negative consequences of auditory deprivation and may allow more efficient acquisition of speech and language.” Some children with a postmeningitis hearing loss under the age of 2 years have received an implant due to “the risk of new bone formation associated with meningitis, which might preclude implantation at a later date.”

### U.S. Preventive Services Task Force Recommendations

Not applicable.

### Medicare National Coverage

Existing national coverage effective for services performed on or after April 4, 2005 states:<sup>59</sup>

“...cochlear implantation may be covered for treatment of bilateral pre- or-post-linguistic, sensorineural, moderate-to-profound hearing loss in individuals who demonstrate limited benefit from amplification.... [which is] defined by test scores of less than or equal to 40% correct in the best-aided listening condition on tape recorded tests of open-set sentence cognition.”

Coverage for cochlear implants may also be provided when the patient has

“...hearing test scores of greater than 40% and less than or equal to 60% only when the provider is participating in, and patients are enrolled in, either an FDA approved category B investigational device exemption clinical trial ..., or a prospective, controlled comparative trial approved by CMS...”

### Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 3.

**Table 3. Summary of Key Trials**

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT03900897 <sup>a</sup>	Expanded Indications in the MED-EL Pediatric Cochlear Implant Population	60	Nov 2023 (active, not recruiting)
NCT04793412	Cochlear Implantation in Children With Asymmetric Hearing Loss or Single-Sided Deafness Clinical Trial	80	Dec 2025 (recruiting)
NCT04506853 <sup>a</sup>	Single-Sided Deafness and Asymmetric Hearing Loss Post-Approval Study	65	Sep 2026 (recruiting)
NCT05154188 <sup>a</sup>	Post Approval Study to Assure the Continued saFety and effectiveness of Neuro Cochlear Implant System in Adult Users (PACIFIC)	60	Feb 2028 (not yet recruiting)
NCT05318417 <sup>a</sup>	A Post-approval, Prospective, Nonrandomized, Single-arm Multicenter Investigation to Evaluate the Safety and Effectiveness of Cochlear Implantation in Children and Adults With Unilateral Hearing Loss/Single-sided Deafness	60	Jun 2027 (recruiting)
<i>Unpublished</i>			
NCT03236909 <sup>a</sup>	Expanded Indications in the Adult Cochlear Implant Population	44	Mar 2023 (completed)
NCT02203305 <sup>a</sup>	Cochlear Implantation in Cases of Single-Sided Deafness	43	Sep 2021 (completed)

NCT No.	Trial Name	Planned Enrollment	Completion Date
NCT05052944	Single-sided Deafness and Cochlear Implantation	78	Nov 2023 (completed)
NCT02379819 <sup>a</sup>	Nucleus Hybrid L24 Implant System: New Enrollment Study	52	Apr 2022 (completed)
NCT03052920	Cochlear Implantation in Adults With Asymmetric Hearing Loss Clinical Trial	40	Mar 2021 (completed)
NCT02105441	Cochlear Implantation Among Adults and Older Children With Unilateral or Asymmetric Hearing Loss	40	Mar 2018 (completed)

NCT: national clinical trial.

<sup>a</sup> Industry-sponsored or co-sponsored trial.

## References

1. Cochlear Implants in Adults and Children. NIH Consens Statement Online. 1995;13(2):1-30.
2. Bond M, Mealing S, Anderson R, et al. The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model. *Health Technol Assess*. Sep 2009; 13(44): 1-330. PMID 19799825
3. Gaylor JM, Raman G, Chung M, et al. Cochlear implantation in adults: a systematic review and meta-analysis. *JAMA Otolaryngol Head Neck Surg*. Mar 2013; 139(3): 265-72. PMID 23429927
4. McRackan TR, Bauschard M, Hatch JL, et al. Meta-analysis of quality-of-life improvement after cochlear implantation and associations with speech recognition abilities. *Laryngoscope*. Apr 2018; 128(4): 982-990. PMID 28731538
5. McRackan TR, Bauschard M, Hatch JL, et al. Meta-analysis of Cochlear Implantation Outcomes Evaluated With General Health-related Patient-reported Outcome Measures. *Otol Neurotol*. Jan 2018; 39(1): 29-36. PMID 29227446
6. Crathorne L, Bond M, Cooper C, et al. A systematic review of the effectiveness and cost-effectiveness of bilateral multichannel cochlear implants in adults with severe-to-profound hearing loss. *Clin Otolaryngol*. Oct 2012; 37(5): 342-54. PMID 22928754
7. Choi JS, Betz J, Li L, et al. Association of Using Hearing Aids or Cochlear Implants With Changes in Depressive Symptoms in Older Adults. *JAMA Otolaryngol Head Neck Surg*. Jul 01 2016; 142(7): 652-7. PMID 27258813
8. van Zon A, Smulders YE, Ramakers GG, et al. Effect of unilateral and simultaneous bilateral cochlear implantation on tinnitus: A Prospective Study. *Laryngoscope*. Apr 2016; 126(4): 956-61. PMID 26255618
9. Bond M, Elston J, Mealing S, et al. Effectiveness of multi-channel unilateral cochlear implants for profoundly deaf children: a systematic review. *Clin Otolaryngol*. Jun 2009; 34(3): 199-211. PMID 19531168
10. Baron S, Blanchard M, Parodi M, et al. Sequential bilateral cochlear implants in children and adolescents: Outcomes and prognostic factors. *Eur Ann Otorhinolaryngol Head Neck Dis*. Apr 2019; 136(2): 69-73. PMID 30314876
11. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): Nucleus 24 Cochlear Implant System (P970051/S172). 2020; [https://www.accessdata.fda.gov/cdrh\\_docs/pdf/P970051S172B.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf/P970051S172B.pdf). Accessed January 1, 2024.
12. Lyu J, Kong Y, Xu TQ, et al. Long-term follow-up of auditory performance and speech perception and effects of age on cochlear implantation in children with pre-lingual deafness. *Chin Med J (Engl)*. Aug 20 2019; 132(16): 1925-1934. PMID 31365431
13. Karltorp E, Eklöf M, Östlund E, et al. Cochlear implants before 9 months of age led to more natural spoken language development without increased surgical risks. *Acta Paediatr*. Feb 2020; 109(2): 332-341. PMID 31350923
14. Sharma A, Dorman MF. Central auditory development in children with cochlear implants: clinical implications. *Adv Otorhinolaryngol*. 2006; 64: 66-88. PMID 16891837

15. Forli F, Arslan E, Bellelli S, et al. Systematic review of the literature on the clinical effectiveness of the cochlear implant procedure in paediatric patients. *Acta Otorhinolaryngol Ital.* Oct 2011; 31(5): 281-98. PMID 22287820
16. Sterkers F, Merklen F, Piron JP, et al. Outcomes after cochlear reimplantation in children. *Int J Pediatr Otorhinolaryngol.* Jun 2015; 79(6): 840-843. PMID 25843784
17. Black J, Hickson L, Black B, et al. Prognostic indicators in paediatric cochlear implant surgery: a systematic literature review. *Cochlear Implants Int.* May 2011; 12(2): 67-93. PMID 21756501
18. Pakdaman MN, Herrmann BS, Curtin HD, et al. Cochlear implantation in children with anomalous cochleovestibular anatomy: a systematic review. *Otolaryngol Head Neck Surg.* Feb 2012; 146(2): 180-90. PMID 22140206
19. Fernandes NF, Morettin M, Yamaguti EH, et al. Performance of hearing skills in children with auditory neuropathy spectrum disorder using cochlear implant: a systematic review. *Braz J Otorhinolaryngol.* 2015; 81(1): 85-96. PMID 25458263
20. Bo D, Huang Y, Wang B, et al. Auditory and Speech Outcomes of Cochlear Implantation in Children With Auditory Neuropathy Spectrum Disorder: A Systematic Review and Meta-Analysis. *Ann Otol Rhinol Laryngol.* Apr 2023; 132(4): 371-380. PMID 35499129
21. Vlastarakos PV, Proikas K, Papacharalampous G, et al. Cochlear implantation under the first year of age--the outcomes. A critical systematic review and meta-analysis. *Int J Pediatr Otorhinolaryngol.* Feb 2010; 74(2): 119-26. PMID 19896223
22. Ching TY, Dillon H, Day J, et al. Early language outcomes of children with cochlear implants: interim findings of the NAL study on longitudinal outcomes of children with hearing impairment. *Cochlear Implants Int.* 2009; 10 Suppl 1(Suppl 1): 28-32. PMID 19067433
23. Colletti L, Mandalà M, Zoccante L, et al. Infants versus older children fitted with cochlear implants: performance over 10 years. *Int J Pediatr Otorhinolaryngol.* Apr 2011; 75(4): 504-9. PMID 21277638
24. Guerzoni L, Murri A, Fabrizi E, et al. Social conversational skills development in early implanted children. *Laryngoscope.* Sep 2016; 126(9): 2098-105. PMID 26649815
25. Lammers MJ, van der Heijden GJ, Pourier VE, et al. Bilateral cochlear implantation in children: a systematic review and best-evidence synthesis. *Laryngoscope.* Jul 2014; 124(7): 1694-9. PMID 24390811
26. Broomfield SJ, Murphy J, Emmett S, et al. Results of a prospective surgical audit of bilateral paediatric cochlear implantation in the UK. *Cochlear Implants Int.* Nov 2013; 14 Suppl 4: S19-21. PMID 24533758
27. Sarant J, Harris D, Bennet L, et al. Bilateral versus unilateral cochlear implants in children: a study of spoken language outcomes. *Ear Hear.* 2014; 35(4): 396-409. PMID 24557003
28. Escorihuela García V, Pitarch Ribas MI, Llópez Carratalá I, et al. Comparative study between unilateral and bilateral cochlear implantation in children of 1 and 2 years of age. *Acta Otorrinolaringol Esp.* 2016; 67(3): 148-55. PMID 26632253
29. Friedmann DR, Green J, Fang Y, et al. Sequential bilateral cochlear implantation in the adolescent population. *Laryngoscope.* Aug 2015; 125(8): 1952-8. PMID 25946482
30. Illg A, Giourgas A, Kral A, et al. Speech comprehension in children and adolescents after sequential bilateral cochlear implantation with long interimplant interval. *Otol Neurotol.* Jun 2013; 34(4): 682-9. PMID 23640090
31. Oh SJ, Mavrommatis MA, Fan CJ, et al. Cochlear Implantation in Adults With Single-Sided Deafness: A Systematic Review and Meta-analysis. *Otolaryngol Head Neck Surg.* Feb 2023; 168(2): 131-142. PMID 35230924
32. Benchetrit L, Ronner EA, Anne S, et al. Cochlear Implantation in Children With Single-Sided Deafness: A Systematic Review and Meta-analysis. *JAMA Otolaryngol Head Neck Surg.* Jan 01 2021; 147(1): 58-69. PMID 33151295
33. Marx M, Mosnier I, Venail F, et al. Cochlear Implantation and Other Treatments in Single-Sided Deafness and Asymmetric Hearing Loss: Results of a National Multicenter Study Including a Randomized Controlled Trial. *Audiol Neurootol.* 2021; 26(6): 414-424. PMID 33789270

34. Peters JPM, van Heteren JAA, Wendrich AW, et al. Short-term outcomes of cochlear implantation for single-sided deafness compared to bone conduction devices and contralateral routing of sound hearing aids-Results of a Randomised controlled trial (CINGLE-trial). *PLoS One*. 2021; 16(10): e0257447. PMID 34644322
35. Buss E, Dillon MT, Rooth MA, et al. Effects of Cochlear Implantation on Binaural Hearing in Adults With Unilateral Hearing Loss. *Trends Hear*. 2018; 22: 2331216518771173. PMID 29732951
36. Dillon MT, Buss E, O'Connell BP, et al. Low-Frequency Hearing Preservation With Long Electrode Arrays: Inclusion of Unaided Hearing Threshold Assessment in the Postoperative Test Battery. *Am J Audiol*. Mar 05 2020; 29(1): 1-5. PMID 31835906
37. Galvin JJ, Fu QJ, Wilkinson EP, et al. Benefits of Cochlear Implantation for Single-Sided Deafness: Data From the House Clinic-University of Southern California-University of California, Los Angeles Clinical Trial. *Ear Hear*. 2019; 40(4): 766-781. PMID 30358655
38. Peter N, Kleinjung T, Probst R, et al. Cochlear implants in single-sided deafness - clinical results of a Swiss multicentre study. *Swiss Med Wkly*. Dec 16 2019; 149: w20171. PMID 31880806
39. Poncet-Wallet C, Mamelle E, Godey B, et al. Prospective Multicentric Follow-up Study of Cochlear Implantation in Adults With Single-Sided Deafness: Tinnitus and Audiological Outcomes. *Otol Neurotol*. Dec 20 2019. PMID 31868784
40. Dillon MT, Buss E, Rooth MA, et al. Cochlear Implantation in Cases of Asymmetric Hearing Loss: Subjective Benefit, Word Recognition, and Spatial Hearing. *Trends Hear*. 2020; 24: 2331216520945524. PMID 32808881
41. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): MED-EL Cochlear Implant System (P000025/S104). 2019; [https://www.accessdata.fda.gov/cdrh\\_docs/pdf/P000025S104B.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf/P000025S104B.pdf). Accessed December 29, 2023.
42. Food and Drug Administration. Post-Approval Studies (PAS): MED-EL New Enrollment SSD/AHL Study. 2020; [https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma\\_pas.cfm?t\\_id=647845&c\\_id=5585](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma_pas.cfm?t_id=647845&c_id=5585). Accessed on January 4, 2024.
43. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): Nucleus 24 Cochlear Implant System (P970051/S205). January 10, 2022; [https://www.accessdata.fda.gov/cdrh\\_docs/pdf/P970051S205B.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf/P970051S205B.pdf). Accessed December 30, 2023.
44. Vlastarakos PV, Nazos K, Tavoulari EF, et al. Cochlear implantation for single-sided deafness: the outcomes. An evidence-based approach. *Eur Arch Otorhinolaryngol*. Aug 2014; 271(8): 2119-26. PMID 24096818
45. Ramos Macías A, Falcón González JC, Manrique M, et al. Cochlear implants as a treatment option for unilateral hearing loss, severe tinnitus and hyperacusis. *Audiol Neurotol*. 2015; 20 Suppl 1: 60-6. PMID 25997672
46. Távora-Vieira D, Marino R, Krishnaswamy J, et al. Cochlear implantation for unilateral deafness with and without tinnitus: a case series. *Laryngoscope*. May 2013; 123(5): 1251-5. PMID 23553411
47. Brown KD, Dillon MT, Park LR. Benefits of Cochlear Implantation in Childhood Unilateral Hearing Loss (CUHL Trial). *Laryngoscope*. Mar 2022; 132 Suppl 6(Suppl 6): S1-S18. PMID 34542181
48. Pillsbury HC, Dillon MT, Buchman CA, et al. Multicenter US Clinical Trial With an Electric-Acoustic Stimulation (EAS) System in Adults: Final Outcomes. *Otol Neurotol*. Mar 2018; 39(3): 299-305. PMID 29342054
49. Food and Drug Administration. Approval Letter: Nucleus Hybrid L24 Cochlear Implant System (P130016). 2014; [https://www.accessdata.fda.gov/cdrh\\_docs/pdf13/P130016a.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130016a.pdf). Accessed January 1, 2024.
50. Roland JT, Gantz BJ, Waltzman SB, et al. United States multicenter clinical trial of the cochlear nucleus hybrid implant system. *Laryngoscope*. Jan 2016; 126(1): 175-81. PMID 26152811

51. Roland JT, Gantz BJ, Waltzman SB, et al. Long-term outcomes of cochlear implantation in patients with high-frequency hearing loss. *Laryngoscope*. Aug 2018; 128(8): 1939-1945. PMID 29330858
52. Lenarz T, James C, Cuda D, et al. European multi-centre study of the Nucleus Hybrid L24 cochlear implant. *Int J Audiol*. Dec 2013; 52(12): 838-48. PMID 23992489
53. Santa Maria PL, Gluth MB, Yuan Y, et al. Hearing preservation surgery for cochlear implantation: a meta-analysis. *Otol Neurotol*. Dec 2014; 35(10): e256-69. PMID 25233333
54. Causon A, Verschuur C, Newman TA. A Retrospective Analysis of the Contribution of Reported Factors in Cochlear Implantation on Hearing Preservation Outcomes. *Otol Neurotol*. Aug 2015; 36(7): 1137-45. PMID 25853614
55. Gantz BJ, Dunn C, Oleson J, et al. Multicenter clinical trial of the Nucleus Hybrid S8 cochlear implant: Final outcomes. *Laryngoscope*. Apr 2016; 126(4): 962-73. PMID 26756395
56. American Academy of Otolaryngology -- Head and Neck Surgery. Position Statement: Cochlear Implants. November 10, 2020; <https://www.entnet.org/resource/position-statement-cochlear-implants/>. Accessed January 2, 2024.
57. Raman G, Lee J, Chung MG, et al. Technology Assessment Report: Effectiveness of Cochlear Implants in Adults with Sensorineural Hearing Loss Rockville, MD: Agency for Healthcare Research and Quality; 2011.
58. National Institute for Health and Care Excellence (NICE). Cochlear Implants for Children and Adults With Severe to Profound Deafness [TA566]. 2019; <https://www.nice.org.uk/guidance/ta566/>. Accessed January 2, 2024.
59. Centers for Medicare & Medicaid. Cochlear Implantation. 2005; <https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=134>. Accessed January 2, 2024.

## Documentation for Clinical Review

### Please provide the following documentation:

- History and physical and/or consultation notes including:
  - Previous treatment plan and response
  - Progress notes for the past six months
  - Hearing test results, if applicable
  - Cochlear implant manufacturer, model, and invoice

### For Upgrade or Replacement:

- Manufacturer warranty information, description of non-function or failure, repair log, and reason component or system cannot be repaired (if applicable)
- Treating provider's progress notes indicating:
  - Type of present device and length of usage
  - Individual's current condition and change in condition (if applicable)
  - Inadequacies of the present system or component
  - Individual's capabilities with his/her current implant and of the requested upgrade or component (if applicable)
  - How the upgrade or component is expected to provide clinically significant improvement (if applicable)

### Post Service (in addition to the above, please include the following):

- Operative/procedures notes (if applicable)

## Coding

*This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy.*

*The following codes are included below for informational purposes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy. Policy Statements are intended to provide member coverage information and may include the use of some codes for clarity. The Policy Guidelines section may also provide additional information for how to interpret the Policy Statements and to provide coding guidance in some cases.*

Type	Code	Description
CPT®	69930	Cochlear device implantation, with or without mastoidectomy
	92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual
	92601	Diagnostic analysis of cochlear implant, patient younger than 7 years of age; with programming
	92602	Diagnostic analysis of cochlear implant, patient younger than 7 years of age; subsequent reprogramming
	92603	Diagnostic analysis of cochlear implant, age 7 years or older; with programming
	92604	Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming
	92605	Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; first hour
	92606	Therapeutic service(s) for the use of non-speech-generating device, including programming and modification
	92607	Evaluation for prescription for speech-generating augmentative and alternative communication device, face-to-face with the patient; first hour
	92608	Evaluation for prescription for speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure)
	92609	Therapeutic services for the use of speech-generating device, including programming and modification
92618	Evaluation for prescription of non-speech-generating augmentative and alternative communication device, face-to-face with the patient; each additional 30 minutes (List separately in addition to code for primary procedure)	
HCPCS	L8614	Cochlear device, includes all internal and external components
	L8615	Headset/headpiece for use with cochlear implant device, replacement
	L8616	Microphone for use with cochlear implant device, replacement
	L8617	Transmitting coil for use with cochlear implant device, replacement
	L8618	Transmitter cable for use with cochlear implant device or auditory osseointegrated device replacement
	L8619	Cochlear implant, external speech processor and controller, integrated system, replacement
	L8621	Zinc air battery for use with cochlear implant device and auditory osseointegrated sound processors, replacement, each

Type	Code	Description
	L8622	Alkaline battery for use with cochlear implant device, any size, replacement, each
	L8623	Lithium ion battery for use with cochlear implant device speech processor, other than ear level, replacement, each
	L8624	Lithium ion battery for use with cochlear implant or auditory osseointegrated device speech processor ear level replacement each
	L8625	External recharging system for battery for use with cochlear implant or auditory osseointegrated device replacement only each
	L8627	Cochlear implant, external speech processor, component, replacement
	L8628	Cochlear implant, external controller component, replacement
	L8629	Transmitting coil and cable, integrated, for use with cochlear implant device, replacement

### Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

Effective Date	Action
03/05/1986	BCBSA Medical Policy adoption
02/28/1991	Policy Revision
07/26/2001	BCBSA Medical Policy adoption
12/01/2006	BCBSA Medical Policy adoption
04/05/2007	BCBSA Medical Policy adoption
12/01/2008	Adopted BCBSA policy "Auditory Brainstem Implants, combined Cochlear Implants and Auditory Brainstem Implants policies, adopted BCBSA policies statements, included benefit allowances and exclusions, policy title change, codes revised.
01/15/2010	Coding Update
10/07/2011	Policy revision without position change
10/05/2012	Policy revision for clarification of replacement/upgrade language
07/31/2015	Title change from Cochlear and Auditory Brainstem Implant Policy revision with position change Policy split into two policies-Cochlear Implant and Auditory Brainstem Implant
02/01/2016	Coding update
09/01/2016	Policy revision with position change
04/01/2017	Policy revision without position change
01/01/2018	Coding update
04/01/2018	Policy revision without position change
04/01/2019	Policy revision without position change
05/01/2020	Annual review. Policy statement, guidelines, and literature updated.
04/01/2024	Policy reactivated. Previously archived from 09/01/2020 to 03/31/2024.

### Definitions of Decision Determinations

**Medically Necessary:** Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished



at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member's illness, injury, or disease.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

### Prior Authorization Requirements and Feedback (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at [www.blueshieldca.com/provider](http://www.blueshieldca.com/provider).

We are interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California or Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration.

For utilization and medical policy feedback, please send comments to: [MedPolicy@blueshieldca.com](mailto:MedPolicy@blueshieldca.com)

*Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.*

**Appendix A**

POLICY STATEMENT	
BEFORE	AFTER <i>Blue font: Verbiage Changes/Additions</i>
<p><b>Reactivated Policy</b></p> <p><b>Policy Statement:</b> N/A</p>	<p><b>Cochlear Implant 7.01.05</b></p> <p><b>Policy Statement:</b></p> <ol style="list-style-type: none"> <li>I. <i>Bilateral or unilateral cochlear implantation of a U.S. Food and Drug Administration (FDA)-approved cochlear implant may be considered <b>medically necessary</b> in individuals who meet <b>all</b> of the following criteria:</i> <ol style="list-style-type: none"> <li>A. <i>Individual’s age is 9 months and older</i></li> <li>B. <i>Individual has bilateral severe-to-profound pre- or post-lingual (sensorineural) hearing loss, defined as a hearing threshold pure-tone average of 70 dB hearing loss or greater at 500, 1000, and 2000 Hz</i></li> <li>C. <i>Individual has shown limited or no benefit from hearing aids</i></li> </ol> </li> <li>II. <i>Cochlear implantation as a treatment for individuals with unilateral hearing loss with or without tinnitus is considered <b>investigational</b>.</i></li> <li>III. <i>The following are considered <b>investigational</b>:</i> <ol style="list-style-type: none"> <li>A. <i>Upgrades of an existing, functioning external system to achieve aesthetic improvement, such as smaller profile components or a switch from a body-worn, external sound processor to a behind-the-ear model</i></li> <li>B. <i>Replacement of internal and/or external components solely for the purpose of upgrading to a system with advanced technology or to a next-generation device</i></li> </ol> </li> <li>IV. <i>Replacement of internal and/or external components may be considered <b>medically necessary</b> only in a small subset of members who have inadequate response to existing component(s) to the point of interfering with the individual’s activities of daily living, or the component(s) is/are no longer functional and cannot be repaired. Copies of original medical records must be submitted either hard copy or electronically to support medical necessity.</i></li> </ol>

POLICY STATEMENT

BEFORE

AFTER

**Blue font: Verbiage Changes/Additions**

- V. Cochlear implantation with a hybrid cochlear implant/hearing aid device that includes the hearing aid integrated into the external sound processor of the cochlear implant (e.g., the Nucleus<sup>®</sup> Hybrid™ L24 Cochlear Implant System) may be considered **medically necessary** for individuals ages 18 years and older who meet **all** of the following criteria:
  - A. Bilateral severe-to-profound high-frequency sensorineural hearing loss with residual low-frequency hearing sensitivity
  - B. Receive limited benefit from appropriately fit bilateral hearing aids
  - C. Have **all** of the following hearing thresholds:
    1. Low-frequency hearing thresholds no poorer than 60 dB hearing level up to and including 500 Hz (averaged over 125, 250, and 500 Hz) in the ear selected for implantation
    2. Severe-to-profound mid- to high-frequency hearing loss (threshold average of 2000, 3000, and 4000 Hz greater than or equal to 75 dB hearing level) in the ear to be implanted
    3. Moderately severe to profound mid- to high-frequency hearing loss (threshold average of 2000, 3000, and 4000 Hz greater than or equal to 60 dB hearing level) in the contralateral ear
    4. Aided consonant-nucleus-consonant word recognition score from 10% to 60% in the ear to be implanted in the preoperative aided condition and in the contralateral ear will be equal to or better than that of the ear to be implanted but not more than 80% correct